Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors

ABSTRACT

Certain Alpha- and Beta-amino acid hydroxyethylamino sulfamic acid derivatives represented by the following formula are useful as retroviral protease inhibitors:

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] The present invention relates to retroviral protease inhibitorsand, more particularly, relates to novel compounds and a composition andmethod for inhibiting retroviral proteases. This invention, inparticular, relates to sulfamic acid derivatives of hydroxyethylamineprotease inhibitor compounds, a composition and method for inhibitingretroviral proteases such as human immunodeficiency virus (HIV) proteaseand for treating a retroviral infection, e.g., an HIV infection. Thesubject invention also relates to processes for making such compounds aswell as to intermediates useful in such processes.

[0003] 2. Related Art

[0004] During the replication cycle of retroviruses, gag and gag-poigene products are translated as proteins. These proteins aresubsequently processed by a virally encoded protease (or proteinase) toyield viral enzymes and structural proteins of the virus core. Mostcommonly, the gag precursor proteins are processed into the coreproteins and the pol precursor proteins are processed into the viralenzymes, e.g., reverse transcriptase and retroviral protease. It hasbeen shown that correct processing of the precursor proteins by theretroviral protease is necessary for assembly of infectious virons. Forexample, it has been shown that frameshift mutations in the proteaseregion of the pol gene of HIV prevents processing of she gag precursorprotein. It has also been shown through site-directed mutagenesis of anaspartic acid residue in the HIV protease that processing of the gagprecursor protein is prevented. Thus, attempts have been made to inhibitviral replication by inhibiting the action of retroviral proteases.

[0005] Retroviral protease inhibition may involve a transition-statemimetic whereby the retroviral protease is exposed to a mimetic compoundwhich binds to the enzyme in competition with the gag and gag-polproteins co thereby inhibit replication of structural proteins and, moreimportantly, the retroviral protease itself. In this manner, retroviralreplication proteases can be effectively inhibited.

[0006] Several classes of compounds have been proposed, particularly forinhibition of proteases, such as for inhibition of HIV protease. Suchcompounds include hydroxyethylamine isosteres and reduced amideisosteres. See, for example, EP O 346 847; EP O 42,541; Roberts et al,“Rational Design of Peptide-Based Proteinase Inhibitors, “Science, 248,358 (1990); and Erickson et al, “Design Activity, and 2.8 Å CrystalStructure of a C₂ Symmetric Inhibitor Complexed to HIV-1 Protease,”Science, 249, 527 (1990).

[0007] Several classes of compounds are known to be useful as inhibitorsof the proteolytic enzyme renin. See, for example, U.S. Pat. No.4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115and U.S. SIR H725 of these, G.B. 2,200,115, GB 2,209,752, EP O 264,795,U.S. SIR H725 and U.S. Pat. No. 4,599,198 disclose urea-containinghydroxyethylamine renin inhibitors. G.B. 2,200,115 also disclosessulfamic acid-containing hydroxyethylamine renin inhibitors, and EP 0264795 discloses certain sulfamic acid-containing hydroxyethylamine renininhibitors. However, it is known that, although renin and HIV proteasesare both classified as aspartyl proteases, compounds which are effectiverenin inhibitors generally cannot be predicted to be effective HIVprotease inhibitors.

BRIEF DESCRIPTION OF THE INVENTION

[0008] The present invention is directed to virus inhibiting compoundsand compositions. More particularly, the present invention is directedto retroviral protease inhibiting compounds and compositions, to amethod of inhibiting retroviral proteases, to processes for preparingthe compounds and to intermediates useful in such processes. The subjectcompounds are characterized as sulfamic acid derivatives ofhydroxyethylamine inhibitor compounds.

DETAILED DESCRIPTION OF THE INVENTION

[0009] In accordance with the present invention, there is provided aretroviral protease inhibiting compound of the formula:

[0010] or a pharmaceutically acceptable salt, prodrug or ester thereofwherein:

[0011] R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,aralkyl, alkoxycarbonyl, aryloxyalkyl, heteroaryloxyalkyl,aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, hydroxyalkyl, aminocarbonyl,aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- anddisubstituted aminoalkanoyl radicals wherein the substituents areselected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkylradicals, or wherein said aminocarbonyl and aminoalkanoyl radicals aredisubstituted, said substituents along with the nitrogen atom to whichthey are attached form a heterocycloalkyl or heteroaryl radical;

[0012] R′ represents hydrogen, radicals as defined for R³ orR″SO₂—wherein R″ represents radicals as defined for R³; or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radicals;

[0013] R¹ represents hydrogen, —CH₂SO₂NH₂, —CH₂CO₂CH₃, —CO₂CH₃, —CONH₂,—CH₂C(O)NHCH₃, —C(CH₃)₂(SH), —C(CH₃)₂(SCH₃), —C(CH₃)₂(SC₆H_(5), —C(CH)₃)₂(S[O]CH₃), —C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl andcycloalkyl radicals, and amino acid side chains selected fromasparagine, —methyl cysteine and methionine and the sulfoxide (SO) andsulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine,leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine,glutamine, threonine, glycine, allo-threonine, serine, O-alkyl serine,aspartic acid, beta-cyanoalanine and valine side chains;

[0014] R¹′ and R¹″ independently represent hydrogen and radicals asdefined for R¹, or one of R¹′ and R¹′, together with R¹ and the carbonatoms to which R¹, R¹′ and R¹″ are attached, represent a cycloalkylradical;

[0015] R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl andaralkyl radicals, which radicals are optionally substituted with a groupselected from alkyl and halogen radials, —NO₂, —CN, —CF₃, —OR⁹ and —SR⁹,wherein R⁹ represents hydrogen and alkyl radicals;

[0016] R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl,alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl andmono- and disubstituted aminoalkyl radicals, wherein said substituentsare selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkylradicals, or in the case of a disubstituted aminoalkyl radical, saidsubstituents along with the nitrogen atom to which they are attached,form a heterocycloalkyl or a heteroaryl radical, and thioalkyl,alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxidederivatives thereof;

[0017] R⁴ and R⁵ independently represent hydrogen and radicals asdefined by R³ or together with a nitrogen atom to which they are bondedform a heterocycloalkyl or a heteroaryl radical, and thioalkyl,alkylthioalkyl and aryl radicals and the sulfone and sulfoxidederivatives thereof;

[0018] R⁶ represents hydrogen and alkyl radicals;

[0019] x represents 1 or 2;

[0020] t represents either 0, 1 or 2; and

[0021] Y represents O, S and NR¹⁵ wherein R¹⁵ represents hydrogen andradicals as defined for R³.

[0022] A family of compounds of particular interest within Formula I arecompounds embraced by Formula II:

[0023] wherein:

[0024] R represents hydrogen, alkyl, alkenyl, cycloalkyl, hydroxyalkyl,aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxycarbonyl,alkoxyalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, andmono- and disubstituted aminocarbonyl and mono- and disubstitutedaminoalkanoyl radicals wherein the substituents are selected from alkyl,aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl.heterocycloalkyl, heterocycloalkyalkyl radicals, or where saidaminoalkanoyl radical or aminocarbonyl radical is disubstituted, saidsubstituents along with the nitrogen atom to which they are attachedform a heterocycloalkyl or heteroaryl radical;

[0025] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0026] R¹ represents hydrogen, —CH₂SO₂NH₂, —CH₂CO₂CH₃, —CO₂CH₃, —CONH₂,—CH₂C(O)NHCH₃, —C(CH₃)₂(SH), —C(CH₃)₂(SCH₃), —C(CH₃)₂(SC₆H₅),—C(CH₃)₂(S[O]CH₃), —C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl,alkynyl and cycloalkyl radicals, and amino acid side chains selectedfrom asparagine, S-methyl cysteine and methionine and the sulfoxide (SO)and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine,alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine,norleucine, glutamine, threonine, glycine, allo-threonine, serine,O-methyl serine, aspartic acid, beta-cyanoalanine and valine sidechains;

[0027] R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl andaralkyl radicals, which radicals are optionally substituted with a groupselected from alkyl and halogen radicals, —NO₂, —C≡N, CF₃, —OR⁹, —SR⁹,wherein R⁹ represents hydrogen and alkyl radicals;

[0028] R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl,alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl andmono- and disubstituted aminoalkyl radicals, wherein said substituentsare selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkylradicals, or in the case of a disubstituted aminoalkyl radical, saidsubstituents along with the nitrogen atom to which they are attached,form a heterocycloalkyl or a heteroaryl radical, and thioalkyl,alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxidederivatives thereof;

[0029] R⁴ and R⁵ independently represent hydrogen and radicals asdefined by R³, or together with the nitrogen atom to which they arebonded represent heterocycloalkyl and heteroaryl radicals.

[0030] A more preferred family of compounds within Formula II consistsof compounds wherein:

[0031] R represents hydrogen, alkyl, alkenyl, cycloalkyl, aryl, aralkyl,alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, aryloxyalkyl, heteroaryloxyalkyl,hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstitutedaminocarbonyl and mono- and disubstituted aminoalkanoyl radicals whereinthe substituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or where said aminocarbonyl oraminoalkanoyl radical is disubstituted, said substituents along with thenitrogen atom to which they are attached form a heterocycloalkyl orheteroaryl radical;

[0032] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0033] R¹ represents CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃), C(CH₃)₂(S[O]CH₃),C(CH₃)₂(S[O]₂CH₃), alkyl, alkenyl and alkynyl radicals, and amino acidside chains selected from the group consisting of asparagine, valine,threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteineand methionine and the sulfone and sulfoxide derivatives thereof,alanine, and allo-isoleucine;

[0034] R² represents alkyl, cycloalkylalkyl and aralkyl radicals, whichradicals are optionally substituted with halogen radicals and radicalsrepresented by the formula —OR⁹ and —SR⁹ wherein R⁹ represents alkylradicals; and

[0035] R³ represents alkyl, haloalkyl, alkenyl, alkoxyalkyl, cycloalkyl,cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyland heteroaralkyl radicals; and

[0036] R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl,cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl,heterocycloalkyl and heterocycloalkylalkyl radicals, or R⁴ and R⁵together with the nitrogen atom to which they are bonded from aheterocycloalkyl or heteroaryl radical.

[0037] Of highest interest are compounds within Formula II wherein

[0038] R represents alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl,cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl,alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl,aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl,heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl,aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyland mono- and disubstituted aminoalkanoyl radicals wherein thesubstituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical isdisubstituted, said substituents along with the nitrogen atom to whichthey are attached form a heterocycloalkyl or heteroaryl radical;

[0039] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0040] R¹ represents CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃), C(CH₃)₂(S[O]CH₃),C(CH₃)₂(S[O]₂CH₃), methyl, propargyl, t-butyl, isopropyl and sec-butylradicals, and amino acid side chains selected from the group Consistingof asparagine, valine, S-methyl cysteine, allo-iso-leucine, iso-leucine,and beta-cyano alanine side chains;

[0041] R² represents CH₃SCH₂CH₂—, iso-butyl, n-butyl, benzyl,4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

[0042] R³ represents propyl, isoamyl, n-butyl, isobutyl, cyclohexyl,cyclohexylmethyl, benzyl and pyridylmethyl radicals; and

[0043] R⁴ and RS independently represent hydrogen and methyl, ethyl,i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl and phenyl radicals, ortogether with the nitrogen atom to which they are bonded form apyrrolidinyl, piperidinyl, morpholinyl, piperazinyl orN′-alkylpiperazinyl radical.

[0044] Another family of compounds of particular interest within FormulaI are compounds embraced by Formula III:

[0045] wherein:

[0046] R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl,cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl,aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl,aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- anddisubstituted aminoalkanoyl radicals wherein the substituents areselected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkylradicals, or where said aminoalkanoyl radical is disubstituted, saidsubstituents along with the nitrogen atom to which they are attachedform a heterocycloalkyl or heteroaryl radical;

[0047] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0048] R¹ represents hydrogen, —CH₂SO₂NH₂, —CH₂CO₂CH₃, —CO₂CH₃, —CONH₂,—CH₂C(O)NHCH₃, —C(CH₃)₂(SH), —C(CH₃)₂(SCH₃), —C(CH₃)₂(S[O]CH₃),—C(CH₃)₂(S(O₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkylradicals, and amino acid side chains selected from asparagine, S-methylcysteine and methionine and the sulfoxide (SO) and sulfone (SO₂)derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine,tert-leucine, phenylalanine, ornithine, histidine, norleucine,glutamine, threonine, glycine, allo-threonine, serine, aspartic acid,beta-cyano alanine and valine side chains;

[0049] R¹′ and R¹″ independently represent hydrogen and radicals asdefined for R¹, or one of R¹′ and R¹″, together with R¹ and the carbonatoms to which R¹, R¹′ and R¹″ are attached, represent a cycloalkylradical;

[0050] R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl andaralkyl radicals, which radicals are optionally substituted with a groupselected from alkyl and halogen radials, —NO₂, —C≡N, CF₃, —OR⁹ and —SR⁹,wherein R⁹ represents hydrogen and alkyl radicals;

[0051] R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl,alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl andmono- and disubstituted aminoalkly radicals, wherein said substituentsare selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkylradicals, or in the case of a disubstituted aminoalkyl radical, saidsubstituents along with the nitrogen atom to which they are attached,form a heterocycloalkyl or a heteroaryl radical, and thioalkyl,alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxidederivatives thereof;

[0052] R⁴ and R⁵ independently represent hydrogen and radicals asdefined by R³, or together with the nitrogen atom to which they arebonded represent heterocycloalkyl and heteroaryl radicals.

[0053] A more preferred family of compounds within Formula III consistsof compounds wherein

[0054] R represents an arylalkanoyl, heteroaroyl, aryloxyalkanoyl,aryloxycarbonyl, alkanoyl, aminocarbonyl, mono-substitutedaminoalkanoyl, or disubstituted aminoalkanoyl, or mono-ordialkylaminocarbonyl radical;

[0055] P′ represents hydrogen and radicals as defined for R³ or R and R¹together with the nitrogen to which they are attached represent aheterocycloalkyl or heteroaryl radical;

[0056] R¹, R^(1′ and R) ¹″ independently represent hydrogen and alkylradicals having from 1 to about 4 carbon atoms, alkenyl, alkynyl,aralkyl radicals, and radicals represented by the formula —CH₂C(O)R″ or—C(O)R″ wherein R″ represents R³⁸, —NR³⁸R³⁹ and OR³⁸ wherein R³⁸ and R³⁹independently represent hydrogen and alkyl radicals having from 1 toabout 4 carbon atoms;

[0057] R² represents alkyl, cycloalkylalkyl and aralkyl radicals, whichradicals are optionally substituted with halogen radicals andradicals-represented by the formula —OR⁹ and —SR⁹ wherein R⁹ representshydrogen and alkyl radicals; and

[0058] R³ represents alkyl, haloalkyl, alkenyl, alkynyl, alkoxyalkyl,cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl,aryl, aralkyl, neteroaryl and heteroaralkyl radicals; and

[0059] R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl,cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl,heterocycloalkyl and heterocycloalkylalkyl radicals, or R⁴ and R⁵together with the nitrogen atom to which they are bonded from aheterocycloalkyl or heteroaryl radical.

[0060] Of highest interest are compounds of Formula III wherein:

[0061] R represents an arylalkanoyl, aryloxycarbonyl, aryloxyalkanoyl,alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, ordisubstituted aminoalkanoyl, or mono-or dialkylaminocarbonyl radical;

[0062] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached represent aheterocycloalkyl or heteroaryl radical;

[0063] R¹, R¹′ and R¹″ independently represent hydrogen, methyl, ethyl,benzyl, phenylpropyl, —C(O)NH₂ and propargyl radicals;

[0064] R² represents CH₃SCH₂CH₂—, iso-butyl, n-butyl, benzyl,

[0065] 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

[0066] R³ represents propyl, isobutyl, isoamyl, n-butyl, cyclohexyl,cyclohexylmethyl, benzyl and pyridylmethyl radicals; and

[0067] R⁴ and R⁵ independently represent hydrogen and methyl, ethyl,i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenylradicals, or together with the nitrogen atom to which they are bondedform a pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl radical.

[0068] Another family of compounds of particular interest within FormulaI are compounds embraced by Formula IV:

[0069] wherein:

[0070] R represents hydrogen, alkyl, alkenyl, cycloalkyl, aryl, aralkyl,aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, alkoxycarbonyl,aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, andmono- and disubstituted aminocarbonyl and mono- and disubstitutedaminoalkanoyl radicals wherein the substituents are selected from alkyl,aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,heterocycloalkyl, heterocycloalkyalkyl radicals, or where saidaminoalkanoyl radical is disubstituted, said substituents along with thenitrogen atom to which they are attached form a heterocycloalkyl orheteroaryl radical;

[0071] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0072] R¹ represents hydrogen, —CH₂SO₂NH₂, —CH₂CO₂CH₃, —CO₂CH₃, —CONH₂,—CH₂C(O)NHCH₃, —C(CH₃,₂(SH), —C(CH₃)₂(SCH₃), —C(CH₃)₂(SC₆H₅),—C(CH₃)₂(S[O]CH₃′, —C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl,alkynyl and cycloalkyl radicals, and amino acid side chains selectedfrom asparagine, S-methyl cysteine and methionine and the sulfoxide (SO)and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine,alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine,norleucine, glutamine, threonine, glycine, allo-threonine, serine,aspartic acid, beta-cyano alanine and valine side chains;

[0073] R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl andaralkyl radicals, which radicals are optionally substituted with a groupselected from alkyl and halogen radicals, —NO₂, —C—N, CF, —OR⁹, —SR⁹,wherein R⁹ represents hydrogen and alkyl;

[0074] R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl,alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl andmono- and disubstituted aminoalkyl radicals, wherein said substituentsare selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkylradicals, or in the case of a disubstituted aminoalkyl radical, saidsubstituents along with the nitrogen atom to which they are attached,form a heterocycloalkyl or a heteroaryl radical, and thioalkyl,alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxidederivatives thereof;

[0075] R⁴ and R⁵ independently represent hydrogen and radicals asdefined for R³ or together with a nitrogen atom to which they are bondedform a heterocycloalkyl or a neteroaryl radical.

[0076] A more preferred family of compounds within Formula IV consistsof compounds wherein

[0077] R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl,cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cyclcalkyl, aryl,aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl,aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- anddisubstituted aminoalkanoyl radicals wherein the substituents areselected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkylradicals, or where said aminoalkanoyl radical is disubstituted, saidsubstituents along with the nitrogen atom to which they are attachedform a heterocycloalkyl or heteroaryl radical;

[0078] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0079] R¹ represents hydrogen, alkyl and alkenyl radicals, and aminoacid side chains selected from the group consisting of asparagine,valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methylcysteine and the sulfone and sulfoxide derivatives thereof, alanine, andallo-isoleucine;

[0080] R² represents alkyl, cycloalkylalkyl and aralkyl radicals, whichradicals are optionally substituted with halogen radicals and radicalsrepresented by the formula —OR⁹ and —SR⁹ wherein R⁹ represents hydrogenand alkyl and halogen radicals;

[0081] R³ represents alkyl, halalkyl, alkenyl, alkoxyalkyl, cycloalkyl,cycloalkylalkyl, heterocycloalkyl, heterocycloalkyalkyl, aryl, aralkyl,heteroaryl and heteroaralkyl radicals; and

[0082] R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl,cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl,heterocycloalkyl and heterocycloalkylalkyl radicals, or R⁴ and R⁵together with the nitrogen atom to which they are bonded from aheterocycloalkyl or heteroaryl radical.

[0083] Of highest interest are compounds within Formula IV wherein

[0084] R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl,cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, andmono- and disubstituted aminocarbonyl and mono- and disubstitutedaminoalkanoyl radicals wherein the substituents are selected from alkyl,aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,heterocycloalkyl, heterocycloalkyalkyl radicals, or where saidaminoalkanoyl radical is disubstituted, said substituents along with thenitrogen atom to which they are attached form a heterocycloalkyl orheteroaryl radical;

[0085] R′ represents hydrogen and radicals as defined for R³ or R and R′together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical;

[0086] R¹ represents hydrogen, methyl, propargyl, t-butyl, isopropyl andsec-butyl radicals, and amino acid side chains selected from the groupconsisting of asparagine, valine, S-methyl cysteine, allo-iso-leucine,iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine, andallo-threonine side chains;

[0087] R² represents CH₃SCH₂CH₂—, iso-butyl, n-butyl, benzyl,4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

[0088] R³ represents propyl, isobutyl, isoamyl, n-butyl, cyclohexyl,cyclohexylmethyl, benzyl and pyridylmethyl radicals; and

[0089] R⁴ and R⁵ independently represent hydrogen and methyl, ethyl,i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenylradicals, or R⁴ and R⁵ together with the nitrogen atom to which they arebonded form a pyrrolidinyl, piperidinyl, morpholinyl or piperazinylradical.

[0090] As utilized herein, the term “alkyl”, alone or in combination,means a straight-chain or branched-chain alkyl radical containing from 1co about 10, preferably from 1 co 8, carbon atoms. Examples of suchradicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like. Theterm “alkenyl”, alone or in combination, means a straight-chain orbranched-chain hydrocarbon radial having one or more double bonds andcontaining from 2 to about 18 carbon atoms preferably from 2 to 8 carbonatoms. Examples of suitable alkenyl radicals include ethenyl, propenyl,1,4-butadienyl, 12-octadecene and the like. The term “alkynyl”, alone orin combination, means a straight-chain hydrocarbon radical having one ormore triple bonds and containing from 2 to about 10 carbon atoms,preferably from 2 to 8 carbon atoms. Examples of alkynyl radicalsinclude ethynyl, propynyl, (propargyl), butynyl and the like. The term“alkoxy”, alone or in combination, means an alkyl ether radical whereinthe term alkyl is as defined above. Examples of suitable alkyl etherradicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy,iso-butoxy, sec-butoxy, tert-butoxy and the like. The term “cycloalkyl”,alone or in combination, means a saturated or partially saturatedmonocyclic, bicyclic or tricyclic alkyl radical wherein each cyclicmoiety contains from about 3 to about 8 carbon atoms and is cyclic. Theterm “cycloalkylalkyl” means an alkyl radical as defined above which issubstituted by a cycloalkyl radical containing from about 3 to about 8,preferably from 3 to 6 carbon atoms. Examples of such cycloalkylradicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl andthe like. The term “aryl”, alone or in combination, means a phenyl ornaphthyl radical which optionally carries one or more substituentsselected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano,haloalkyl and the like, such as phenyl, p-tolyl, 4-methoxyphenyl,4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hyaroxyphenyl,1-naphthyl, 2-naphthyl, and the like. The term “aralkyl”, alone or incombination, means an alkyl radical as defined above in which onehydrogen atom is replaced by an aryl radical as defined above, such asbenzyl, 2-phenylethyl and the like. The term “aralkoxy carbonyl”, aloneor in combination, means a radical of the formula —C(O)—O-aralkyl inwhich the term “aralkyl” has the significance given above, n example ofan aralkoxycarbonyl radical is benzyloxycarbonyl. The term “aryloxy”means a radical of the formula aryl-O- in which the term aryl has thesignificance given above. The term “alkanoyl”, alone or in combination,means an acyl radical derived from an alkanecarboxylic acid whereinalkane means a radical as defined above for alkyl. Examples of alkanoylradicals include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl,and the like. The term “cycloalkylcarbonyl” means an acyl grout derivedfrom a monocyclic or bridged cycloalkanecarboxylic acid such ascyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and thelike, or from a benz-fused monocyclic cycloalkanecarboxylic acid whichis optionally substituted by, for example, alkanoylamino, such as1,2,3,4-tetrahydro-2-naphthoyl,2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl.The term “aralkanoyl” means an acyl radical derived from anaryl-substituted alkanecarboxylic acid such as phenylacetyl,3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl,4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl,and the like. The term proyl” means an acyl radical derived from anaromatic carboxylic acid. Examples of such radicals include aromaticcarboxylic acids, an optionally substituted benzoic or naphthoic acidsuch as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl,4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl,3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like.The heterocyclyl or heterocycloalkyl portion of a heterocyclylcarbonyl,heterocyclyloxycarbonyl, heterocyclylalkoxycarbonyl, or heterocyclyalkylgroup or the like is a saturated or partially unsaturated monocyclic,bicyclic or tricyclic heterocycle which contains one or more heteroatoms selected from nitrogen, oxygen and sulphur, which is optionallysubstituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo,and the like, and/or on a secondary nitrogen atom i.e. —NH—) by alkyl,aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiarynitrogen atom (i.e. ═N—) by oxido and which is attached via a carbonatom. The heteroaryl portion of a heteroaroyl, heteroaryloxycarbonyl, ora heteroaralkoxy carbonyl group or the like is an aromatic monocyclic,bicyclic, or tricyclic heterocycle which contains the hetero atoms andis optionally substituted as defined above with respect to thedefinition of heterocyclyl. Such heterocyclyl and heteroaryl radicalshave from four to about 12 ring members, preferably from 4 to 10 ringmembers. Examples of such heterocyclyl and heteroaryl groups arepyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl,pyrrolyl, imidazolyl (e.g., imidazol 4-yl,1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, pyrazinyl,pyrimidinyl, furyl, thienyl, triazolyl, oxazolyl, thiazoiyl, indolyl(e.g., 2-indolyl, etc.), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl,1-oxido-2-quinolinyl, etc.), isoquinolinyl (e.g., 1-isoquinolinyl,3-isoquinolinyl, etc.), tetrahydroquinolinyl (e.g.,1,2,3,4-tetrahydro-2-quinolyl, etc.), 1,2,3,4-tetrahydroisoquinolinyl(e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, etc., quinoxalinyl,β-carbolinyl, 2-benzofurancarbonyl, 1-,2-,4- or 5-benzimidazolyl, andthe like. The term “cycloalkylalkoxycarbonyl” means an acyl groupderived from a cycloalkylalkoxycarboxylic acid of the formulacycloalkylalkyl-O—COOH wherein cycloalkylalkyl has the significancegiven above. The term “aryloxyalkanoyl” means an acyl radical of theformula aryl-O-alkanoyl wherein aryl and alkanoyl have the significancegiven above. The term “heterocyclyloxycarbonyl” means an acyl groupderived from heterocyclyl-O-COOH wherein heterocyclyl is as definedabove. The term “heterocyclylalkanoyl” is an acyl radical derived from aheterocyclyl-substituted alkane carboxylic acid wherein heterocyclyl hasthe significance given above. The term “heterocyclylalkoxycarbonyl”means an acyl radical derived from a heterocyclyl-substitutedalkane-O-COOH wherein heterocyclyl has the significance given above. Theterm “heteroaryloxycarbonyl” means an acyl radical derived from acarboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl hasthe significance given above. The term “aminocarbonyl” alone or incombination, means an amino-substituted carbonyl (carbamoyl) groupderived from an amino-substituted carboxylic acid wherein the aminogroup can be a primary, secondary or tertiary amino group containingsubstituents selected from hydrogen, and alkyl, aryl, aralkyl,cycloalkyl, cycloalkylalkyl radicals and the like. The term“aminoalkanoyl” means an acyl group derived from an amino-substitutedalkanecarboxylic acid wherein the amino group can be a primary,secondary or tertiary amino group containing substituents selected fromhydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicalsand the like. The term “halogen” means fluorine, chlorine, bromine oriodine. The term “haloalkyl” means an alkyl radical having thesignificance as defined above wherein one or more hydrogens are replacedwith a halogen. Examples of such haloalkyl radicals includechloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl,trifluoromethyl, 1,1,1-triflucroethyl and the like. The term “leavinggroup” generally refers co groups readily displaceable by a nucleophile,such as an amine, a thiol or an alcohol nucleophile. Such leaving groupsare well known in the art. Examples of such leaving groups include, butare not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole,halides, triflates, tosylates and the like. Preferred leaving groups areindicated herein where appropriate.

[0091] Procedures for preparing the compounds of Formula I are set forthbelow. It should be noted that the general procedure is shown as itrelates to preparation of compounds having the specifiedstereochemistry, for example, wherein the absolute stereochemistry aboutthe hydroxyl group is designated as (R), which is the preferredstereochemistry for the compounds of the present invention. However,such procedures are generally applicable to those compounds of oppositeconfiguration, e.g., where the stereochemistry about the hydroxyl groupis (S) in addition, the compounds having the (R) stereochemistry can beutilized to produce those having the (S) stereochemistry. For example, acompound having the (F) stereochemistry can be inverted to the (S)stereochemistry using well-known methods.

Preparation of Compounds of Formula I

[0092] The compounds of the present invention represented by Formula 1above can be prepared utilizing the following general procedure. Thisprocedure is schematically shown in the following Schemes I and II:

[0093] An N-protected chloroketone derivative of an amino acid havingthe formula:

[0094] wherein P represents an amino protecting group, and R² is asdefined above, is reduced to the corresponding alcohol utilizing anappropriate reducing agent. Suitable amino protecting groups are wellknown in the art and include carbobenzoxy, t-butoxycarbonyl, and thelike. A preferred amino protecting group is carbobenzoxy. A preferredN-protected chloroketone is N-benzyloxycarbonyl-L-phenylalaninechloromethyl ketone. A preferred reducing agent is sodium borohydride.The reduction reaction is conducted at a temperature of from −10° C. toabout 25° C., preferably at about 0° C., in a suitable solvent systemsuch as, for example, tetrahydrofuran, and the like. The N-protectedchloroketones are commercially available, e.g., such as from Bachem,Inc., Torrance, Calif. Alternatively, the chloroketones can be preparedby the procedure set forth in S. J. Fittkau, J. Prakt. Chem., 315, 1037(1973), and subsequently N-protected utilizing procedures which are wellknown in the art.

[0095] The halo alcohol can be utilized directly, as described below,or, preferably, is then reacted, preferably at room temperature, with asuitable base in a suitable solvent system to produce an N-protectedamino epoxide of the formula:

[0096] wherein P and R² are as defined above. Suitable solvent systemsfor preparing the amino epoxide include ethanol, methanol, isopropanol,tetrahydrofuran, dioxane, and the like including mixtures thereof.Suitable bases for producing the epoxide from the reduced chloroketoneinclude potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBUand the like preferred base is potassium hydroxide.

[0097] Alternatively, a protected amino epoxide can be prepared startingwith an L-amino acid which is reacted with a suitable amino-protectinggroup in a suitable solvent to produce an amino-protected L-amino acidester of the formula:

[0098] wherein p¹ and p² independently represent hydrogen, benzyl andamino-protecting groups (as defined above), provided that P¹ and P² arenot both hydrogen; P³ represents carboxyl-protecting group, e.g.,methyl, ethyl, benzyl, tertiary-butyl and the like; and R² as definedabove.

[0099] The amino-protected L-amino acid ester is then reduced, to thecorresponding alcohol. For example, the amino-protected L-amino acidester can be reduced with diisobutylaluminum hydride at −78° C. in asuitable solvent such as toluene. The resulting alcohol is thenconverted, for example, by way of a Swern oxidation, to thecorresponding aldehyde of the formula:

[0100] wherein P¹, P² and R² are as defined above. Thus, adichloromethane solution of the alcohol is added to a cooked (−75 to−68° C.) solution of oxalyl chloride in dichloromethane and DMSO indichloromethane and stirred for 35 minutes.

[0101] The aldehyde resulting from the Swern oxidation is then reactedwith a halomethyllithium reagent, which reagent is generated a situ byreacting an alkyllithium or arylithium compound with a dihalomethanerepresented by the formula X¹CH₂X² wherein X¹ and X² independentlyrepresent I, Br or Cl. For example, a solution of the aldehyde andchloroiodomethane in THF is cooled to −78° C. and a solution ofn-butyllithium in hexane is added. The resulting product is a-mixture ofdiastereomers of the corresponding amino-protected epoxides of theformulas:

[0102] The diastereomers can be separated e.g., by chromatography, or,alternatively, once reacted in subsequent steps the diastereomericproducts can be separated. For compounds having the (S) stereochemistry,a D-amino acid can be utilized in place of the L-amino acid.

[0103] The amino epoxide is then reacted, in a suitable solvent system,with an equal amount, or preferably an excess of, a desired amine of theformula:

R³NH₂

[0104] wherein R³ is hydrogen or is as defined above. The reaction canbe conducted over a wide range of temperatures, e.g., from about 10° C.to about 100°C., but is preferably, but not necessarily, conducted at atemperature at which the solvent begins to reflux. Suitable solventsystems include protic, non-protic and dipolar aprotic organic solventssuch as, for example, those wherein the solvent is an alcohol, such asmethanol, ethanol, isopropanol, and the like, ethers such astetrahydrofuran, dioxane and the like, and toluene,N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. Apreferred solvent is isopropanol. Exemplary amines corresponding to theformula R³NH₂ include benzyl amine, isobutylamine, n-butyl amine,isopentyl amine, isoamylamine, cyclohexanemethyl amine, naphthylenemethyl amine and the like. The resulting product is a 3-(N-protectedamino)-3-(R²)-1-(NHR³)-propan-2-ol derivative (hereinafter referred toas an amino alcohol) can be represented by the formulas:

[0105] wherein P, P¹, p², R² and R³ are as described above.Alternatively, a haloalcohol can be utilized in place of the aminoepoxide.

[0106] The amino alcohol defined above is then reacted in a suitablesolvent with a sulfamoyl halide, e.g. sulfamoyl chloride (R⁴R⁵NSO₂Cl orR⁴HNSO₂Cl) or sulfamoyl anhydride in the presence of an acid scavenger.Suitable solvents in which the reaction can be conducted includemethylene chloride, tetrahydrofuran. Suitable acid scavengers includetriethylamine, pyridine. The resulting sulfamic acid derivative can berepresented, depending on the epoxide utilized, by the formulas;

[0107] wherein P, P¹, P², R², R³, R⁴ and R⁵ are as defined above. Theseintermediates are useful for preparing inhibitor compounds of thepresent invention and are also active inhibitors of retroviralproteases.

[0108] The sulfamoyl halides of the formula R⁴NHSO₂X can be prepared bythe reaction of _suitable isocyanate of the formula R⁴NCO with fumingsulfuric acid to produce the corresponding sulfamate which is thenconverted to the halide by well know-m procedures, such as by treatingthe sulfamate with PCl₅. Alternatively the isocyanate can be treatedwith chlorosulfonic acid to produce the corresponding sulfamoyl chloridedirectly.

[0109] The sulfamoyl halides of the formula R⁴R⁵NSO₂Cl can be preparedby reacting an amine of the formula R⁴R⁵NH, preferably as a salt such asthe hydrochloride, with sulfuryl chloride in a suitable solvent such asacetonitrile. The reaction mixture is gradually warmed to refluxtemperature and maintained at the reflux temperature until the reactionis complete. Alternatively, sulfamoyl halides of the formula R⁴R⁵NSO₂Clcan be prepared by reacting an amine of the formula R⁴R⁵NH with sulfurylchloride in boiling MeCN as disclosed in Matier et al., J. Med. Chem.,15, No. 5, p.538 (1972).

[0110] Following preparation of the sulfamic acid derivative, the aminoprotecting group P or p¹ and p² amino protecting groups are removedunder conditions which will not affect the remaining portion of themolecule. These methods are well known in the art and include acidhydrolysis, hydrogenolysis and the like. A preferred method involvesremoval of the protecting group, e.g., removal of a carbobenzoxy group,by hydrogenolysis utilizing palladium on carbon in a suitable solventsystem such as an alcohol, acetic acid, and the like or mixturesthereof. Where the protecting group is a t-butoxycarbonyl group, it canbe removed utilizing an inorganic or organic acid, e.g., HCl ortrifluoroacetic acid, in a suitable solvent system, e.g., dioxane ormethylene chloride. The resulting product is the amine salt derivative.Following neutralization of the salt, the amine is then reacted with anamino acid or corresponding derivative thereof represented by theformula (PN[CR¹′ R¹″]_(t) CH(R¹)COOH) wherein t, R¹, R¹′ and R¹″ are asdefined above, to produce the antiviral compounds of the presentinvention having the formula:

[0111] wherein t, P, R¹, R¹′, R¹″, R², R³, R⁴ and R⁵ are as definedabove. Preferred protecting groups in this instance are abenzyloxycarbonyl group or a t-butoxycarbonyl group. Where the amine isreacted with a derivative of an amino acid, e.g., when t=1 and R¹′ andR¹″ are both H, so that the amino acid is a O-amino acid, such β-aminoacids can be prepared according to the procedure set forth in acopending application, U.S. Ser. No. 07/345,808, where t is 1, one ofR¹′ and R¹″ is H and R¹ is hydrogen so that the amino acid is ahomo-β-amino acid, such homo-β-amino acids can be prepared by theprocedure set forth in a copending application, U.S. Ser. No.07/853,561. Where t is O and R¹ is alkyl, alkenyl, alkynyl, cycloalkyl,—CH₂SO₂NH₂, —CH₂CO₂CH₃, —CO₂CH₃, —CONH₂, —CH₂C(O)NHCH₃, —C(CH₃)₂ (SH),—C(CH₃)₂(SCH₃), —C(CH₃)₂[S(O)CH₃], —C(CH₃)₂[S(O₂)CH₃], or an amino acidside chain, such materials are well known and many are commerciallyavailable from Sigma-Aldrich.

[0112] The N-protecting group can be subsequently removed, if desired,utilizing the procedures described above, and then reacted with acarboxylate represented by the formula:

[0113] wherein R is as defined above and L is an appropriate leavinggroup such as a halide. Preferably, where R¹ is a side chain of anaturally occurring α-amino acid, R is a 2-quinoline carbonyl groupderived from N-hydroxysuccinimide-2-quinoline carboxylate, i.e., L ishydroxy succinimide. A solution of the free amine (or amine acetatesalt) and about 1.0 equivalent of the carboxylate are mixed in anappropriate solvent system and optionally treated with up to fiveequivalents of a base such as, for example, N-methylmorpholine, at aboutroom temperature. Appropriate solvent systems include tetrahydrofuran,methylene chloride or N,N-dimethylformamide, and the like, includingmixtures thereof.

[0114] Alternatively, the protected amino alcohol from the epoxideopening can be further protected at the newly introduced amino groupwith a protecting group P′ which is not removed when the firstprotecting P is removed one skilled in the art can choose appropriatecombinations of P and P′. One suitable choice is when P is Cbz and P′ isBoc. The resulting compound represented by the formula:

[0115] can be carried through the remainder of the synthesis to providea compound of the formula:

[0116] and the new protecting group PI is selectively removed, andfollowing deprotection, the resulting amine reacted to form the sulfamicacid derivative as described above. This selective deprotection andconversion to the sulfamic acid can be accomplished at either the end ofthe synthesis or at any appropriate intermediate step if desired.

[0117] It is contemplated that for preparing compounds of the Formulashaving R⁶, the compounds can be prepared following the procedure setforth above and, prior to coupling the sulfonamide derivative or analogthereof, e.g. coupling to the amino acid PNH(CH₂)_(t)CH(R¹)COOH, carriedthrough a procedure referred to in the arc as reductive amination. Thus,a sodium cyanoborohydride and an appropriate aldehyde or ketone can bereacted with the sulfonamide derivative compound or appropriate analogat room temperature in order to reductively aminate any of the compoundsof Formulas I-IV. It is also contemplated that where R³ of the aminoalcohol intermediate is hydrogen, the inhibitor compounds of the presentInvention wherein R³ is alkyl, or other substituents wherein the α-Ccontains at least one hydrogen, can be prepared through reductiveamination of the final product of the reaction between the amino alcoholand the amine or at any other stage of the synthesis for preparing theinhibitor compounds.

[0118] Contemplated equivalents of the general formulas set forth abovefor the antiviral compounds and derivatives as well as the intermediatesare compounds otherwise corresponding thereto and having the samegeneral properties, such as tautomers thereof as well as compounds,wherein one or more of the various R groups are simple variations of thesubstituents as defined therein, e.g., where R is a higher alkyl groupthan that indicated. En addition, where a substituent is designated as,or can be, a hydrogen, the exact chemical nature of a substituent whichis other than hydrogen at that position, e.g., a hydrocarbyl radical ora halogen, hydroxy, amino and the like functional group, is not criticalso long as it does not adversely affect the overall activity and/orsynthesis procedure.

[0119] The chemical reactions described above are generally disclosed interms of their broadest application to the preparation of the compoundsof this invention. Occasionally, the reactions may not be applicable asdescribed to each compound included within the disclosed scope. Thecompounds for which this occurs will be readily recognized by thoseskilled in the art. In all such cases, either the reactions can besuccessfully performed by conventional modifications known to thoseskilled in the art, e.g., by appropriate protection of interferinggroups, by changing to alternative conventional reagents, by routinemodification of reaction conditions, and the like, or other reactionsdisclosed herein or otherwise conventional, will be applicable to thepreparation of the corresponding compounds of this invention. In allpreparative methods, all starting materials are known or readilypreparable from known starting materials.

[0120] Without further elaboration, it is believed that one skilled inthe art can, using the preceding description, utilize the presentinvention co its fullest extent. The following preferred specificembodiments are, therefore, to be construed as merely illustrative, andnot limitative of the remainder of the disclosure in any way whatsoever.

[0121] The following Examples 1 through 9 illustrate preparation ofintermediates. These intermediates are useful in preparing the inhibitorcompounds of the present invention as illustrated in Examples 13-17. Inaddition, the intermediates of Examples 4-9 are also retroviral proteaseinhibitors and inhibit, in particular, HIV protease.

EXAMPLE 1

[0122]

[0123] Preparation of N[3 (S) -benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isoamylamine

[0124] Part A:

[0125] To a solution of 75.0 g (0.226 mol) ofN-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of807 mL of methanol and 807 mL of tetrahydrofuran at −2° C., was added13.17 g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over onehundred minutes. The solvents were removed under reduced pressure at 40°C. and the residue dissolved in ethyl acetate (approx. 1L). The solutionwas washed sequentially with 1M potassium hydrogen sulfate, saturatedsodium bicarbonate and then saturated sodium chloride solutions. Afterdrying over anhydrous magnesium sulfate and filtering, the solution wasremoved under reduced pressure. To the resulting oil was added hexane(approx. 1L) and mixture warmed to 60° C. with swirling. After coolingto room temperature, the solids were collected and washed with 2L ofhexane. The resulting solid was recrystallized from hot ethyl acetateand hexane to afford 32.3 g (43% yield) ofN-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp150-151° C. and M+Li⁺=340.

[0126] Part B:

[0127] To a solution of 6.52 g (0.116 mol, 1.2 equiv.) of potassiumhydroxide in 968 mL of absolute ethanol at room temperature, was added32.3 g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol.After stirring for fifteen minutes, the solvent was removed underreduced pressure and the solids dissolved in methylene chloride. Afterwashing with water, drying over magnesium sulfate, filtering andstripping, one obtains 27.9 g of a white solid. Recrystallization fromhot ethyl acetate and hexane afforded 22.3 g (77% yield) ofN-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C. and MH⁺ 298.

[0128] Part C:

[0129] A solution of N-benzyloxycarbonyl3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00 g, 3.36 mmol) andisoamylamine (4.90 g, 67.2 mmol, 20 equiv.) in 10 mL of isopropylalcohol was heated to reflux for 1.5 hours. The solution was cooled toroom temperature, concentrated in vacuo and then poured into 100 mL ofstirring hexane whereupon the product crystallized from solution. Theproduct was isolated by filtration and air dried to give 1.18 g, 95% ofN=[[3(S)-phenylmethylcarbamoyl)amino-2(R)-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)]aminemp 108.0-109.5°C., MH⁺ mz=371.

EXAMPLE 2

[0130]

[0131] Preparation ofN,N-dibenzyl-3(S)-amino-1.2-(S)-epoxy-4-phenylbutane

[0132] Step A:

[0133] A solution of L-phenylalanine (50.0 g, 0.302 mol), sodiumhydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605mol) in water (500 ml) is heated to 97° C. Benzyl bromide (108.5 ml,0.912 mol) is then slowly added (addition time −25 min). The mixture isthen stirred at 97° C. for 30 minutes. The solution is cooled to roomtemperature and extracted with toluene (2×250 ml). The combined organiclayers are then washed with water, brine, dried over magnesium sulfate,filtered and concentrated to give an oil product. The crude product isthen used in the next step without purification.

[0134] Step B:

[0135] The crude benzylated product of the above step is dissolved intoluene (750 ml) and cooled to −550C. A 1.5 M solution of DIBAL-H intoluene (443.9 ml, 0.666 mol) is then added at a rate to maintain thetemperature between −55° to −5000 (addition time—-1 hour). The mixtureis stirred for 20 minutes at −550C. The reaction is quenched at −550C bythe slow addition of methanol (37 ml). The cold solution is then pouredinto cold (5° C.) 1.5 N HCl solution (1.8 L). The precipitated solid(approx. 138 g) is filtered off and washed with toluene. The solidmaterial is suspended in a mixture of toluene (400 ml) and water (100ml). The mixture is cooled to 5° C., treated with 2.5 N NaOH (186 ml)and then stirred at room temperature until the solid is dissolved. Thetoluene layer is separated from the aqueous phase and washed with waterand brine, dried over magnesium sulfate, filtered and concentrated to avolume of 75 ml (89 g). Ethyl acetate (25 ml) and hexane (25 ml) arethen added to the residue upon which the alcohol product begins tocrystallize. After 30 min., an additional 50 ml hexane is added topromote further crystallization. The solid is filtered off and washedwith 50 ml hexane to give approximately 35 g of material. A second cropof matrial can be isolated by refiltering the mother liquor. The solidsare combined and recrystallized from ethyl acetate (20 ml) and hexane(30 ml) to give, in 2 crops, approximately 40 g (40% fromL-phenylalanine) of analytically pure alcohol product. The motherliquors are combined and concentrated (34 g). The residue is treatedwith ethyl acetate and hexane which provides an additional 7 g (˜7%yield) of slightly impure solid product. Further optimization in therecovery from the mother liquor is probable. Step C:

[0136] A solution of oxalyl chloride (8.4 ml, 0.096 mol) indichloromethane (240 ml: is cooled to −740C. solution of DMSO (12.0 ml,0.155 mol) in dichloromethane 50 ml) is then slowly added at a rate tomaintain the temperature at −74° (addition time ˜1.25 hr). The mixtureis stirred for 5 min. followed by addition of a solution of the alcohol(0.074 mol) in 100 ml of dichloromethane (addition time −20 min., temp.−75° C. to −68° C.) The solution is stirred at −78° C. for 35 minutes.Triethylamine (41.2 ml, 0.295 mol) is then added over 10 min. (temp.−780 to −68° C.) upon which the ammonium salt precipitated. The coldmixture is stirred for 30 min. and then water (225 ml) is added. Thedichloromethane layer is separated from the aqueous phase and washedwith water, brine, dried over magnesium sulfate, filtered andconcentrated. The residue is diluted with ethyl acetate and hexane andthen filtered to further remove the ammonium salt. The filtrate isconcentrated to give the desired aldehyde product. The aldehyde wascarried on to the next step without purification.

[0137] Temperatures higher than −70° C. have been reported in theliterature for the Swern oxidation. Other Swern modifications andalternatives to the Swern oxidations are also possible.

[0138] A solution of the crude aldehyde 0.074 mol and chloroiodomethane(7.0 ml, 0.096 mol) in tetrahydrofuran (285 ml) is cooled to −78° C. A1.6 M solution of n-butyllithium in hexane (25 ml, 0.040 mol) is thenadded at a rate to maintain the temperature at −75° C. (addition time−15 min.). After the first addition, additional chloroiodomethane (1.6ml, 0.022 mol) is added again, followed by n-butyllithium (23 ml, 0.037mol), keeping the temperature at −75° C. The mixture is stirred for 15min. Each of the reagents, chlorolodomethane (0.70 ml, 0.010 mol) andn-butyllithium (5 ml, 0.008 mol) are added 4 more times over 45 min. at−75° C. The cooling bath is then removed and the solution warmed to 22°C. over 1.5 hr. The mixture is poured into 300 ml of saturated aq.ammonium chloride solution. The tetrahydrofuran layer is separated. Theaqueous phase is extracted with ethyl acetate (1×300 ml). The combinedorganic layers are washed with brine, dried over magnesium sulfate,filtered and concentrated to give a b rown oil (27.4 g). The productcould be used in the next step without purification. The desireddiastereomer can be purified by recrystallization at a subsequent step.

[0139] Alternately, the product could he purified by chromatography.

EXAMPLE 3

[0140]

[0141] Preparation ofN[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine

[0142] A solution ofN-benzyloxycarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenyl butane (50.0 g,0.168 mol) and isobutylamine (246 g, 3.24 mol, 20 equivalents) in 650 mLof isopropyl alcohol was heated to reflux for 1.25 hours. The solutionwas cooled to room temperature, concentrated in vacuo and then pouredinto 1 L of stirring hexane whereupon the product crystallized fromsolution. The product was isolated by filtration and air dried to give57.56 g, 92% ofN-[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine, at108.0-109.5° C., MH+ m/z=371.

EXAMPLE 4

[0143]

[0144] Preparation ofphenylmethyl[2R-hydroxy-3-[[(dimethylamino)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate

[0145] The product from Example 3 (740 mg, 2.0 mmol) anddiisopropylethylamine (382 uL, 2.2 mmol) were dissolved indichloromethane (1.5 mL) at room temperature. To this was addeddimethylsulfamoyl chloride (354 uL, 3.3 mmol). The reaction was stirredfor 24 hours. The reaction mixture was chromatographed on silica gel (50gm) using 1% ethanol in chloroform. The product fractions were pooledand concentrated to an oil. Anal. Calcd for C₂₄H₃₅N₃O₅S: C, 60.35; H,7.39; N, 8.80. Found: C, 60.18; H, 7.40; N, 8.55.

EXAMPLE 5

[0146]

[0147] Preparation ofphenylmethyl[2R-hydroxy-3-[[(dimethylamino)sulfonyl](3-methylbutyl)amino]-1S-(phenylmethyl)propyl]carbamate

[0148] Part A

[0149] The procedure described in Example 1 was used to prepareN-[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-[(3-methylbutyl)]amine.

[0150] Part B

[0151] The product from Part A (192 mg, 0.5 mmol) anddiisopropylethylamine (96 uL, 0.55 mmol) were dissolved indichloromethane (10 mL) at room temperature. To this was addeddimethylsulfamoyl chloride (59 uL, 0.55 mmol). The reaction was stirredfor 120 hours, then concentrated on a rotary evaporator. The residue waschromatographed on silica gel (50 gm) using 2% methanol indichloromethane. The product fractions were pooled and concentrated toan oil which solidified on standing. Anal. Calcd for C₂₅H₃₇N₃O₅S.0.9H₂O: C, 59.13; H. 7.64; N, 8.27; S, 6.1. Found: C, 58.81; H, 7.38; N,8.62; S, 6.70.

EXAMPLE 6

[0152]

[0153] Preparation of phenylmethyl [3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]carbamate

[0154] Part A:

[0155] To a stirred solution of 3.88 gm (2 mL) of 30% fuming sulfuricacid in nitromethane (10 mL) was added dropwise n-butylisocyanate (3.83mL, 34 mmoles) at 0 C. After the addition was completed, the suspensionwas heated in an oil bath at 120 C. for 30 min The reaction was cooledand filtered. The collected sulfamic acid crystals were air dried, wt.4.73 gm (91%).

[0156] Part B:

[0157] A suspension of n-butyl sulfamic acid (1.92 gm, 12.53 mmoles) andphosphorus pentachloride 12.61 gm, 12.53 mmoles) in benzene (20·mL) waswarmed gently to initiate gas evolution. The reaction mixture wasstirred at room temperature for 0.5 h., during which time a cloudysolution resulted. The cloudy solution was heated to reflux for 0.5 h.,then was concentrated. The product n-butyl sulfamoyl chloride wasisolated by vacuum distillation (120 C., 300 millitorr), 730 mg (liq.)(34%).

[0158] Part C:

[0159] The amine alcohol from Example 3 (370 mg, 1 mmole) was dissolvedin 3 mL of dichloromethane and treated with diisopropylethylamine (278uL, 2 mmoles), followed by chlorotrimethylsilane (126 uL; 1 mmole). Thereaction mixture was stirred at r.t. for 1 h. n-Butyl sulfamoyl chloridefrom Part B (171 mg, 1 mmole) was added and the mixture was stirred atr.t. overnight. After removal of dichloromethane the oily residue wastaken up in ethyl acetate and washed successively with 5% citric acid,saturated sodium bicarbonate, brine, dried over sodium sulfate and thesolvent was evaporated to give 512 mg of product (oil).

[0160] The oily product (510 mg) was dissolved in dichloromethane (3 mL)and was treated with 2 mL of 4N HCl in dioxane After 15 min. methanol (5mL) was added and the solution was stirred for an additional 15 minSolvent and excess reagent were evaporated. The product was isolated bysilica gel chromatography co give 357 mg of phenylmethyl[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S--(phenylmethyl)propyl]carbamate.Anal. Calcd for C₂₆H₃₉N₃O₅S: C, 61.76; H,7.77; N,8.31. Found: C, 61.89;H,7.66; N, 3.18.

EXAMPLE 7

[0161]

[0162] Preparation of phenylmethyl[2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate

[0163] Part A:

[0164] 1-methylpiperazine hydrochloride (3.46 gm, 20 mmoles) was addedin portions within 15 min. to a stirred solution of sulfuryl chloride(8.99 gm, 67 mmoles) in acetonitrile(40 mL). The suspension wasgradually warmed to reflux and maintained at reflux temperatureovernight. A brown solution was obtained. After cooling CD r.t., thecrystals were collected by filtration, wt. 2.3 gm. A sample of4-methyl-1-piperazine sulfamoyl chloride.HCl was recrystallized frommethanol. anal. Calcd. for C₅H₁₂N₂O₂Cl₂S: C, 25.54; H, 5.14; N, 11.91;Cl, 30.16. Found: C, 25.54; H, 4.91; N, 11.91; Cl, 29.88.

[0165] Part B:

[0166] N-[3 (S) -benzyloxycarbonylamino-2 (R)-hydroxy-4-phenylbutyl]-N-isobutylamine (370 mg, 1.0 mmole), preparedaccording to the procedure in Example 3 was mixed with DIEA (280 uL, 2.0mmoles) and 4-methyl-1-piperazine sulfamoyl chloride.HCl (240 mg, 1.0mmole) in 6 mL of dichloromethane. The reaction mixture was stirred for5 days. After filtration, the filtrate was concentrated to an oil, whichwas taken up in ethyl acetate. The ethyl acetate solution was washedwith sodium bicarbonate solution, brine and dried over sodium sulfate.After evaporation, phenylmethyl[2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyil](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate was obtained(412 mg).

EXAMPLE 8

[0167]

[0168] Preparation of phenylmethyl[2R-hydroxy-3-[[(1,1-dimethyl)amino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate

[0169] Part A:

[0170] A 25 mL two-necked RB flask, equipped with a reflux condenser anddropping funnel and under a nitrogen atmosphere, was charged witht-butanol (207 uL, 2.2 mmoles) and 5 mL of hexane. Chlorosulfonylisocyanate (192 uL, 2.2 mmoles) in 3 mL of hexane was added dropwise.Upon warming a homogeneous solution was obtained. The solution washeated at gentle reflux for 45 min., When was cooled to r.t. Solvent wasremoved under a steady scream of nitrogen. The crude t-butyl sulfamoylchloride to liquid, was used without further purification.

[0171] Part B:

[0172] N[3(S) -benzyloxycarbonylamino-2 (R)-hydroxy-4-phenylbutyl]-N-isobutylamine (370 mg, 1.0 mmole), preparedaccording to the procedure in Example 3 was mixed with DIEA (139 uL, 1mmole) in 5 mL of dichloromethane. Chlorotrimethylsilane (126 uL, 1mmole) was added. After 1 h., additional DIEA (160 uL) was added,followed by a dichloromethane solution (5 mL) containing 1.1 mmole oft-butyl sulfamoyl chloride from Part A. The reaction mixture was stirredfor 2 days. Solvent was removed under aspirator pressure. The oilyresidue was taken up in ethyl acetate and washed with 5% citric acid,saturated sodium bicarbonate, brine, dried over sodium sulfate andevaporated to an oily residue (380 mg).

[0173] The crude product was stirred in 4N HCl in dioxane (6 mL) for 15min. After the addition of 4 mL of methanol to the reaction mixture, thesolution was stirred for an additional 15 min, then concentrated to anoily residue. The product, phenylmethyl(2R-hydroxy-3-[[(1,1-dimethylethyl)amino[sulfonyl[(2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate was obtainedafter silica gel chromatography (188 mg, 37%). MS (MH)⁺=506.

EXAMPLE 9

[0174] Preparation of phenylmethyl [2R-hydroxy-3-[[(piperidyl)sulfonYl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate

[0175] Part A

[0176] The product of Example 3 (750 mg, 2.02 mmol) and triethylamine280 uL, 2.02 mmol. were dissolved in dichloromethane (8.0 mL) at roomtemperature. To this was added piperidinesulfamoyl chloride (371 mg,2.02 mmol). The reaction was stirred for 72 hours and then concentrated.The residue was chromatographed on silica gel (50 gm) using 5% methanolin dichloromethane. The product fractions were pooled and concentratedto an oil, 945 mg. TLC (silica/5% MeOH in CH2Cl2) showed two spots.Rechromatographed. Anal. Calcd for C27H39N3O5S: C, 62.63; H, 7.51; N,8.06. Found: C, 62.64; H, 7.59; N, 8.12.

[0177] Part B:

[0178] The product of Part A (430 mg) was combined with 10% Pd/C inmethanol (10 mL) and hydrogenated at 5 psi for 1.4 hours at roomtemperature. The catalyst was removed by filtration and the solventevaporated to afford the product as an oil, 305 mg.

[0179] Part C:

[0180] To a solution of Cbz-L-t-leucine (236 mg, 0.89 mmol) in DMF;² mL)was added HOBt 0.115 mg, 0.85 mmol) and EDC (163 mg, 0.85 mmol). Thereaction was stirred at room temperature for 1 hour and then a solutionof the product from part B (305 mg, 0.79 mmol) in DMF (2 mL) was added.The reaction was stirred for 18 hours then concentrated. The residue wastaken up in ethyl acetate and washed with 0.5% HCl solution, saturatedaqueous NaHCO3, and saturated aqueous NaCd (50 mL each). The organicsolution was dried (Na₂SO₄), filtered and concentrated to a foam, 410mg. 1H NMR supports product.

[0181] Part D:

[0182] The product of Part C (410 mg) was combined with 10% Pd/C inmethanol (10 mL) and hydrogenated at 5 psi for 2.0 hours at roomtemperature. The catalyst was removed by filtration and the solventevaporated to afford the product as an foam, 320 mg.

[0183] Part E:

[0184] To a solution of the product of Part D (310 mg, 0.62 mmol) indichloromethane (10 mL) was added diisopropylethylamine (130 uL, 0.75mmol) and chloroacetic anhydride (117 mg, 0.68 mmol) at 0 C. Thereaction was allowed to warm to room temperature and stir one hour. Thesolvent was removed and the residue taken up in ethyl acetate (50 mL).The organic solution was washed with 5% citric acid, saturated NaHCO3,and saturated NaCl (50 mL each). The solution was dried (Na2SO4),filtered and concentrated to give a solid, 350 mg.

[0185] Part F:

[0186] The product of Part E (350 mg, 0.61 mmol) was combined with 40%aqueous dimethylamine (280 uL, 3.05 mmol) in isopropanol (10 mL). Thereaction was stirred for 18 hours then concentrated. The residue wastaken up in ethyl acetate (50 mL) and washed with water, saturatedNaHCO3, and saturated NaCl (50 mL each). The solution was dried(Na2SO4), filtered and concentrated to a solid. The solid waschromatographed on silica gel using 2% MeOH in dichloromethane. Theproduct fractions were pooled and concentrated to give a white solid.Anal. Calcd for C29H51N5O5S. 0.25H₂O: O, 59.41; H, 8.77; N, 11.94.Found: O, 59.35; H, 8.78; N, 11.63.

EXAMPLE 10

[0187] Following the procedures of the previous Examples 1-9, theintermediate compounds set forth in Tables 1A, 1B and 1C were prepared.TABLE 1A

R³ R⁴ R⁵ isobutyl CH₃ CH₃ isoamyl CH₃ CH₃ isobutyl CH₂CH₂CH₂CH₃ Hisobutyl C(CH₃)₃ H

[0188] TABLE 1B

Entry R⁴ R⁵ 1 CH₃ CH₃ 2 H CH₃ 3 H (CH₂)₃CH 4 H CH(CH₃)₂ 5 H C(CH₃)₃ 6 Hcyclohexyl 7 R⁴ & R⁵ = pyrrolidinyl

[0189] TABLE 1C

Entry R³ R⁴ R⁵ A isobutyl methyl H B p-fluorobenzyl methyl methyl Cisobutyl isopropyl H D isobutyl

E isobutyl phenyl H F isobutyl

G isobutyl

H benzyl t-butyl H I cyclohexylmethyl t-butyl H J isobutyl C(CH₃)₂CO₂MeH K cyclohexyl t-butyl H L isobutyl (CH₂)₂OCH₂C₆H₅ H M isobutylcyclohexyl H

[0190] The following Examples 11-13 illustrate preparation of β-aminoacid intermediates. These intermediates can be coupled to theintermediate compounds of Examples 1-10 to produce inhibitor compoundsof the present invention containing β-amino acids.

EXAMPLE 11

[0191] A. Preparation of 4(4-methoxybenzyl)itaconate

[0192] A 5 L three-necked round bottomed flask equipped with constantpressure addition funnel, reflux condenser, nitrogen inlet, andmechanical stirrer was charged with itaconic anhydride (660.8 g, 5.88mol) and toluene (2300 mL). The solution was warmed to reflux andtreated with 4-methoxybenzyl alcohol (812.4 g, 5.88 mol) dropwise over a2.6 h period. The solution was maintained at reflux for an additional1.5 h and then the contents were poured into three 2 L erlenmeyer flasksto crystallize. The solution was allowed to cool to room temperaturewhereupon the desired mono-ester crystallized. The product was isolatedby filtration on a Buchner funnel and air dried to give 850.2 g, 58% ofmaterial with mp 83-85° C., a second crop, 17% was isolated aftercooling of the filtrate in an ice bath. ¹H NMR (CDCl₃) 300 MHz 7.32(d,J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 6.49(s, 1H), 5.85(s, 1H), 5.12(s,2H), 3.83(s, 3H), 3.40(s, 2H).

[0193] B. Preparation of Methyl 4(4-methoxybenzyl) itaconate

[0194] A 5 L three-necked round bottomed flask equipped with refluxcondenser, nitrogen inlet, constant pressure addition funnel andmechanical stirrer was charged with 4(4-methoxybenzyl) itaconate (453.4g, 1.81 mol) and treated with 1,5-diazabicyclo[4.3.0]non-5-ene (275.6 g,1.81 mol), (DBN), dropwise so that the temperature did not rise above15° C. To this stirring mixture was added a solution of methyl iodide(256.9 g, 1.81 mol) in 250 mL of toluene from the dropping funnel over a45 m period. The solution was allowed to warm to is room temperature andstirred for an additional 3.25 h.

[0195] The precipitated DBN hydroiodide was removed by filtration,washed with toluene and the filtrate poured into a separatory funnel.The solution was washed with sat. aq. NaHCO₃ (2×500 mL), 0.2N HCl (1×500mL), and brine (2×500 mL), dried over anhyd. MgSO₄, filtered, and thesolvent removed in vacuo. This gave a clear colorless oil, 450.2 g, 94%whose NMR was consistent with the assigned structure. ¹H NMR (CDCl₃) 300MHz 7.30(d, J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 2H), 6.34(s, 1H), 5.71(s,1H), 5.09(s, 2H), 3.82(s, 3H), 3.73(s, 3H), 3.38(s, 2H). ¹³C NMR (CDCl₃)170.46, 166.47, 159.51, 133.55, 129.97, 128.45, 127.72, 113.77, 66.36,55.12, 51.94, 37.64.

[0196] C. Preparation of Methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate

[0197] A 500 mL Fisher-Porter bottle was charged with methyl4(4-methoxybenzyl) itaconate (71.1 g, 0.269 mol), rhodium (R,R) DiPAMPcatalyst (204 mg, 0.269 mmol 0=1 mol %) and degassed methanol (215 mL).The bottle was flushed 5 times with nitrogen and 5 times with hydrogento a final pressure of 40 psig. The hydrogenation commenced immediatelyand after ca. 1 h the uptake began to taper off, after 3 h the hydrogenuptake ceased and the bottle was flushed with nitrogen, opened and thecontents concentrated on a rotary evaporator to give a brown oil thatwas taken up in boiling iso-octane (ca. 200 mL, this was repeatedtwice), filtered through a pad of celite and the filtrate concentratedin vacuo to give 66.6 g, 93% of a clear colorless oil, ¹H NMR (CDCl₃,300 MHz 7.30(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 5.08(s, 2H),3.82(s, 3H), 3.67(s, 3H), 2.95(ddq, J=5.7, 7.5, 8.7 Hz, 1H), 2.79(dd,J=8.1, 16.5 Hz, 1H), 2.45(dd, J=5.7, 16.5 Hz, 1H), 1.23(d, J=7.5 Hz,3H).

[0198] D. Preparation of Methyl 2(R)-methylsuccinate

[0199] A. 3 L three-necked round-bottomed flask equipped with a nitrogeninlet, mechanical stirrer, reflux condenser and constant pressureaddition funnel was charged with methyl 4(4-methoxybenzyl)2(R)-methylsuccinate (432.6 g, 1.65 mol) and toluene (1200 mL). Thestirrer was started and the solution treated with trifluoroacetic acid(600 mL from the dropping funnel over 0.25 h. The solution turned a deeppurple color and the internal temperature rose to 45° C. After stirringfor 2.25 h the temperature was 27° C. and the solution had acquired apink color. The solution was concentrated on a rotary evaporator. Theresidue was diluted with water (2200 mL) and sat. aq. NaHCO₃ (1000 mL).Additional NaHCO₃ was added until the acid had been neutralized. Theaqueous phase was extracted with ethyl acetate (2×1000 mL) to remove theby-products and the aqueous layer was acidified to pH=1.8 with conc.HCl. This solution was extracted with ethyl acetate (4×1000 mL), washedwith brine, dried over anhyd. MgSO₄, filtered and concentrated on arotary evaporator to give a colorless liquid 251 g, >100% that wasvacuum distilled through a short path apparatus cut 1: bath temperature120° C. @ >1 mm, bp 25-29° C.; cut 2: bath temperature 140° C. a 0.5 mm,bp 95-108° C., 151 g, [α]_(d) @ 25° C.=+1.38° C.(c=15.475, MeOH),[α]_(d)=+8.48° C. (neat); cut 3: bath temperature 140° C., bp 108° C.,36 g, [α]_(d) @ 25° C=+1.49° C.(c=15.00, MeOH), [α]_(d) =+8.98° C.(neat). Cuts 2 and 3 were combined to give 189 g, 78% of product, ¹H NMR(CDCl₃) 300 MHz 11.6(brs, 1H), 3.72(s, 3H), 2.92(ddq, J=5.7, 6.9, 3.0Hz, 1H), 2.81(dd, J=8.0, 16.8 Hz, 1H), 2.47(dd, J=5.7, 16.8 Hz, 1H),1.26(d, J=6.9 Hz, 3H).

[0200] E. Preparation of Methyl Itaconate

[0201] A 50 mL round bottomed flask equipped with reflux condenser,nitrogen inlet and magnetic stir bar was charged with methyl4(4-methoxybenzyl) itaconate (4.00 g, 16 mmol, 12 mL of touluene and 6ml of trifluoroacetic acid. The solution was kept at room temperaturefor 15 hours and then the volatiles were removed in vacuo. The residuewas taken up in ethyl acetate and extracted three times with saturatedaqueous sodium bicarbonate solution. The combined aqueous extract wasacidified to pH=1 with aqueous potassium bisulfate and then extractedthree times with ethyl acetate. The combined ethyl acetate solution waswashed with saturated aqueous sodium chloride, dried over anhydrousmagnesium sulfate, filtered, and concentrated in vacuo. The residue wasthen vacuum distilled to give 1.23 g, 75% of pure product, bp 85-87 @0.1 mm. ¹H NMR (CDCl₃) 300 MHz 6.34(s, 1H), 5.73(s, 2H), 3.76(s, 3H),3.38(s, 2H). ¹³C NMR (CDCl₃) 177.03, 166.65, 129.220, 132.99, 52.27,37.46.

[0202] F. Curtius Rearrangement of Methyl 2(R)-methylsuccinate:Preparation of Methyl N-Moz-α-methyl β-alanine.

[0203] A 5L four necked round bottomed flask equipped with a nitrogeninlet, reflux condenser, mechanical stirrer, constant pressure additionfunnel, and thermometer adapter was charged with methyl2(R)-methylsuccinate (184.1 g, 1.26 mol), triethylamine (165.6 g, 218mL, 1.64 mol, 1.3 equivalents), and toluene (1063 mL). The solution waswarmed to 85° C. and then treated dropwise with a solution ofdiphenmiphosohoryl azide (346.8 g, 1.26 mol) over a period of 1.2 h. Thesolution was maintained at that temperature for an additional 1.0 h andthen the mixture was treated with 4-methoxybenzyl alcohol 174.1 g, 1.26mol) over a 0.33 h period from the dropping funnel. The solution wasstirred at 88° C. for an additional 2.25 h and then cooled to roomtemperature. The contents of the flask were poured into a separatoryfunnel and washed with sat. aq. NaHCO₃ (2×500 mL), 0.2N HCl (2×500 mL),brine (1×500 mL), dried over anhyd. MgSO₄, filtered, and concentrated invacuo to give 302.3 g, 85% of the desired product as a slightly brownoil. ¹H NMR (CDCl₃) 300 MHz 7.32(d, J=8.4 Hz, 2H), 6.91(d, J=8.4 Hz,2H), 5.2(brm, 1H), 5.05(s, 2H), 3.83(s, 3H), 3.70(s, 3H), 3.35(m, 2H),2.70(m, 2H), 1.20(d, J=7.2 Hz, 3H).

[0204] G. Hydrolysis of Methyl N-Moz-α-methyl β-alanine: Preparation ofα-methyl β-alanine Hydrochloride

[0205] A 5 L three-necked round bottomed flask equipped with a refluxcondenser, nitrogen inlet and mechanical stirrer was charged with methylN-Moz-α-methyl β-alanine (218.6 g, 0.78 mol), glacial acetic acid (975mL) and 12N hydrochloric acid (1960 mL). The solution was then heated toreflux for 3 h. After the solution had cooled to room temperature (ca. 1h) the aqueous phase was decanted from organic residue (polymer) and theaqueous phase concentrated on a rotary evaporator. Upon addition ofacetone to the concentrated residue a slightly yellow solid formed thatwas slurried with acetone and the white solid was isolated by filtrationon a Buchner funnel. The last traces of acetone were removed byevacuation to give 97.7 g, 90% of pure product, mp 128.5-120.5° C.[α]_(d) @ 25° C.=9.0° C. (c=2.535, Methanol). ¹H NMR (D₂O) 300 MHz3.29(dd, j=8.6, 13.0 Hz, 1H), 3.16(dd, J=5.0, 13.0 m Hz, 1H), 2.94(ddq,J=7.2, 5.0, 8.6 Hz, 1H), 1.30(d,J=7.2 Hz, 3H); ¹³c NMR (D₂O) 180.84,44.56, 40.27, 17.49.

[0206] H. Preparation of N-Boc α-Methyl β-Alanine

[0207] A solution of a-methyl b-alanine hydrochloride (97.7 g, 0.70 mol)in water (1050 mL) and dioxane (1050 mL) the pH was adjusted to 8.9 with2.9N NaOH solution. This stirring solution was then treated withdi-tert-butyl pyrocarbonate (183.3 g, 0.84 mol, 1.2 equivalents) all atonce. The pH of the solution was maintained between 8.7 and 9.0 by theperiodic addition of 2.5N NaOH solution. After 2.5 h the pH hadstabilized and the reaction was judged to be complete. The solution wasconcentrated on a rotary evaporator (the temperature was maintained at<40° C.). The excess di-tert-butyl pyrocarbonate was removed byextraction with dichloromethane and then the aqueous solution wasacidified with cold 1N HCl and immediately extracted with ethyl acetate(4×1000 ML). The combined ethyl acetate extract was washed with brine,dried over anhyd. MgSO₄, filtered and concentrated on a rotaryevaporator to give a thick oil 127.3 g, 90% crude yield that was stirredwith n-hexane whereupon crystals of pure product formed, 95.65 g, 67%,mp 76-78° C., [α]_(d) @ 25° C.=−11.8° C. (c=2.4, EtOH). A second cropwas obtained bag concentration of the filtrate and dilution with hexane,15.4 g, for a combined yield of 111.05 g, 78%. ¹H NMR (acetone D₆) 300MHz 11.7 (brs, 1H), 6.05 (brs 1H), 3.35 (m, 1H), 3.22 (m, 1H), 2.50 (m,1H), 1.45(s, 9H), 1.19 (d, J=7.3 Hz, 3H); ¹³C NMR (acetone D₆) 177.01,79.28, 44.44, 40.92, 29.08, 15.50. Elemental analysis calc'd. forC₉H₁₇NO₄: C, 53.19, H, 8.42; N, 6.89. Found: C, 53.36; H, 8.46; N, 6.99.

[0208] I. Preparation of N-4-Methoxybenzyloxycarbonyl α-Methyl β-Alanine

[0209] A solution of N-4-Methoxybenzyloxycarbonyl α-methyl β-alaninemethyl ester (2.81 g, 10.0 mmol) in 30 mL of 25% aqueous methanol wastreated with lithium hydroxide (1.3 equivalents) at room temperature fora period of 2 h. The solution was concentrated V vacuo and the residuetaken up in a mixture of water and ether and the phases separated andthe organic phase discarded. The aqueous phase was acidified withaqueous potassium hydrogen sulfate to pH=1.5 and then extracted threetimes with ether. The combined ethereal phase was washed with saturatedaqueous sodium chloride solution, dried over anhydrous magnesiumsulfate, filtered and concentrated i vacuo to give 2.60 g, 97% ofN-4-Methoxybenzyloxycarbonyl α-methyl β-alanine (N-Moz-AMBA) which waspurified by recrystallization from a mixture of ethyl acetate and hexaneto give 2.44 g, 91% of pure product, mp 96-97° C., MH⁺=268. ¹H NMR(D₆-acetone/300 MHz) 1.16 (3H, d, J=7.2 Hz), 2.70 (1H, m), 3.31 (2H, m),3.31 (3H, s), 4.99 (2H, s), 6.92 (2H, 4, J=8.7 Hz), 7.13 (2H, d, J=8.7Hz).

EXAMPLE 12

[0210] Following generally the procedure of Example 11, the β-aminoacids set forth in Table 2 were prepared. TABLE 2

Entry R¹ R¹′ R¹″ 1 —CH₃ H H 2 —CH(CH₃)₂ H H 3 —C(CH₃)₃ H H 4 H H H 5 H—CH₃ H 6 H —CH₃ —CH₃ 7 H H —CO2CH₃ 8 H H —CONH₂ 9 —CH₂CH₃ H H 10—CH₂CH(CH₃)₂ H H 11 —CH₂C₆H₅ H H 12

H H 13

H H 14 —CH₂COOH H H 15 H —CH(CH₃)₂ H 16 H —CH₂CH(CH₃)₂ H 17 H

H 18 H

H 19 H

H 20 H

H 21 H —(CH₂)₃CH(C₆H₅)₂ H

EXAMPLE 13

[0211] Utilizing generally the procedure set forth in Example 11, thefollowing β-amino acid compounds were prepared.

EXAMPLE 14

[0212]

[0213] Preparation of N-[3-[[(butylamino)sulfonyl](2-methylproryl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[[2-(dimethylamino)-1-oxoethyl]amino]dimethylbutanamide

[0214] Part A:

[0215] The product from Example 3 (357 mg, 0.71 mmol) in 10 mL ofmethanol was hydrogenated over 10% palladium on carbon (60 mg) for 5 hr.The mixture was then filtered through Celite and concentrated to givethe product as an oil (213 mg). Part B:

[0216] The free amine from Part A (210 mg, 0.566 mmol) was coupled withN-CBZ-L-t-butylglycine (180 mg, 0.679 mmol) in the presence ofN-hydroxybenzotriazole (92 mg, 0.679 mmol) and EDC (130 mg, 0.679 mmol)to yield 275 mg of phenylmethyl [[[1S-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-amino]carbonyl]-2,2-dimethylpropyl]carbamateafter Purification on silica column.

[0217] Part C:

[0218] The product from Part B (235 mg);in methanol was hydrogenatedover 10% palladium on carbon (50 mg) for 4 h. The mixture was filteredthrough Celite and concentrated to give the product as an oil (173 mg,0.369 mmol). This free amine was then dissolved in 3 mL ofdichloromethane and acylated with bromo acetyl chloride (34 uL, 0.406mmol) in the presence of DIEA (62 uL, 0.443 mmol) for 2 h. The crudemixture (190 mg, 0.32 mmol) was dissolved in 1 mL of isopropanol andmixed with a 40% wt dimethylamine in water (180 uL, 1.6 mmol) andstirred overnight. Solvent and excess reagents were evaporated. The oilyresidue was taken up in ethylacetate, washed with saturated sodiumbicarbonate, brine and dried over sodium sulfate. The productN-[3-[[(butylamino)-sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-(dimethylamino)-1-oxoethyl]amino]3,3-dimethylbutanamidewas purified by silica gel chromatography. Anal. Calc'd for C₂₈H₅₁N₅O₅S.0.5H2O: C, 58.10; H, 9.06; N, 12.09. Found: C, 57.81; H, 8.44; N. 12.01.EI MS M+=569.

EXAMPLE 15

[0219]

[0220] Preparation ofN1-[2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-guinolinylcarbonyl)amino]butanediamide

[0221] Part A:

[0222] A solution of the carbamate from Example 7 (412 mg, 0.77 mmoles)containing 20 mL methanol and 5 mL acetic acid was hydrogenated over 10%palladium on carbon (30 mg) for 6 h. After filtration of the reactionmixture, the filtrate was evaporated to an oil. The oily residue wasdissolved in ethyl acetate and washed with sodium bicarbonate solution.The organic layer was evaporated to give the free amine (100 mg).

[0223] Part B:

[0224] The free amine from Part A (80 mg, 0.20 mmoles) was coupled withN-BOC-L-asparagine (61 mg, 0.264 mmoles) in the presence ofN-hydroxybenzotriazole (48 mg, 0.35 mmoles) and EDC (50 mg, 0.264mmoles) to yield 125 mg ofN1[2R-hydroxy-3-[3-[(4-methyl-1-piperaziny)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butanediamide.

Part C:

[0225] N1[2R-hydroxy-3-[3-[(4-methyl-1-piperaziny)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butanediamide (118 mg, 0.19 mmole) was stirred in 4N HCl in dioxane (5 mL) atr.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness.The product was dried in vacuo. This material (116 mg, 0.19 mmoles) wasthen reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester(53 mg, 0.19 mmoles), DIEA (83 uL, 0.60 mmoles) in DMF (1 mL) overnight.The product N1-[2R-hydroxy-3-[,(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamidwas purified by silica gel chromatography. Anal. Calcd for C₃₃H₄₅N₇O₆S.0.5H₂O/0.3 CH₃CH₂OCH₂CH₃: C,58.76; H,7.06; N, 14.03. Found: C, 58.23; H,6.98; N, 13.81.

EXAMPLE 16

[0226]

[0227] Preparation of N1-[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-guinolinylcarbonyl)amino]butanediamide

[0228] Part A:

[0229] The procedures described in Example 6, Parts A-C, were used toprepare phenylmethyl [3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl] carbamate. Amethanolic solution of this carbamate (460 mg, 0.796 mmoles) washydrogenated over 10% palladium on carbon (90 mg) to give the free amine(329 mg).

[0230] Part B:

[0231] The free amine from Part A. (266 mg, 0.6 mmoles) was coupled withN-BOC-L-asparagine (167 mg, 0.72 mmoles) in the presence ofN-hydroxybenzotriazole (130 mg, 0.96 mmoles) and EDC (138 mg, 0.72mmoles) to yield 306 mg of N1[2R-hydroxy-3-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butanediamide after purification on a silica column.

[0232] Part C:

[0233] N1[2R-hydroxy-3-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]l-2S-[(1,1-dimethylethoxycarbonyl)amino]butanediamide (150 mg, 0.26 mmoles) was stirred in 4N HCl in dioxane (4 mL) atr.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness.The product was dried in vacuo. This material (140 mg, 0.26 mmoles) wasthen reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester(70 mg; 0.26 mmoles), DIEA (72 uL, 0.52 mmloles) in dichloromethane (2mL) overnight. The product-N1-[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamidewas purified by silica gel chromatography. Anal. Calcd for C₃₂H₄₄N₆O₆S:C,59.98; H,6.92; N, 13.12. Found: C, 59.98; H, 6.65; N, 12.72.

EXAMPLE 17

[0234]

[0235] Preparation of N1-[3[-[[(1,1-dimethylehtyll)amino]sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-r(2-quinolinylcarbonyl)amino]butanediamide

[0236] Part A:

[0237] A 20 mL methanol solution of phenylmethyl[2R-hydroxy-3-[[(1,1-dimethylethyl)sulfonyl](2-methylpropyl)amino]-1s-(phenylmethyl)propyl] carbamate from Example 8(170 mg, 0.33 mmoles) was hydrogenated over 10% palladium on carbon (40mg). The resulting free amine (110 mg, 0.30 mmole) was coupled withN-BOC-L-asparagine (84 mg, 0.36 mmoles) in the presence ofN-hydroxybenzotriazole (65 mg, 0.48 mmoles) and EDC (69 mg, 0.36 mmoles)to yield 160 mg ofN1[2R-hydroxy-3-[3-([(1,1-dimethylethyl)aminolsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(1,1-dimethylethoxycarbonyl)amino]butanediamide.

[0238] Part B:

[0239]N1[2R-hydroxy-3-[3-[[(1,1-dimethylethyl)amino]sulfonyl];2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butanediamide (150 mg, 0.25 mmole) was stirred in 4N HCl in dioxane (5 mL, atr.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness.The product was dried in vacuo. This material (135 mg, 0.25 mmoles) wasthen reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester(70 mg, 0.25 mmoles), DIEA (72 uL, 0.52 mmoles) in DMF (1 mL) overnight.The product N1-[3[-[[(1,1-dimethylehtyl)amino]sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl)-2S-[(2-quinolinylcarbonyl)amino]butanediamidewas purified by silica gel chromatography (85 mg, 53%). Anal. Calcd forC₃₂H₄₄N₆O₆S. 0.8H₂O: C,58.66; H,7.02; N, 12.83. Found: C, 59.00; H,6.84; N; 12.54.

Example 18

[0240]

[0241] Preparation of N′-[3-[[(N,N-dimethylamino)sulfonyl](3-methylbutyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide

[0242] Part A:

[0243] Preparation ofN-3(S)-(Benzyloxycarbonyl)-amino-2(R)-hydroxy-4-phenylbutylamine,N-(3-methylbutyl). A solution of 20 g (67 mmol) ofN-benzyloxycarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane in 140 mL ofisopropyl alcohol was treated with 83 g (952 mmol) of isoamylamine andrefluxed for one hour. The solution was cooled, concentrated, hexaneadded and the resulting solid filtered to afford 22.4 g of the desiredproduct.

[0244] Part B:

[0245] Preparation ofN-3(S)-(Benzyloxycarbonyl)-amino-2(R)-hydroxy-4-phenylbutylamine,N-(3-methylbutyl)-N-(t-butyloxycarbonyl). To a solution of 22.4 g (58.3mmol) of product from Part A above, 6.48 g (64.1 mmol) of triethylamineand 150 mg of N,N-dimethyl-4-aminopyridine in 200 mL of tetrahydrofuranat 0° C. was added 12.7 g (58.3 mmol) of di-t-butylpyrocarbonate in 10mL of THF.(After 3.5 hours at room temperature, the volatiles wereremoved, ethyl acetate added and washed with 5% citric acid, sat'dNaHCO₃. dried and concentrated to afford 30 g of crude product.Chromatography on silica gel using 20% ethyl acetate/hexane afforded22.5 g (79%) of the desired product.

[0246] Part C:

[0247] Preparation ofN-3(S)-[N-benzyloxycarbonyl-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine,N-(3-methylbutyl)-N-(t-butyloxycarbonyl). A solution of 22.5 g ofproduct from Part B above in 200 mL of ethanol was hydrogenated over 5.9g of 10% palladium-on-carbon under 50 psig hydrogen for one hour. Thecatalyst was filtered and the solvent removed under reduced pressuretoafford 15.7 g of free amine. This was dissolved in 130 mL of DMF and4.54 g (44.9 mmol) of N-methylmorpholine an added to a mixture of 13.3 g(49.9 mmol) N-benzyloxy-carbonyl-L-asparagine, 11.5 g (74.9 mmol) ofN-hydroxybenzotriazole and 10.5 g (54.9 mmol) of EDCl in 120 mL of DMFat 0° C., which had been preactivated for one hour prior to theaddition. The mixture was stirred for 2 hours at 0° C. and then for 12hours at room temperature. The reaction was poured into 1L of sat'daqueous sodium bicarbonate, the solid collected, dissolved in ethylacetate, washed with water, sat'd sodium bicarbonate, 5% citric acid andbrine, dried and concentrated to afford 16.7 g of the desired product.

[0248] Part D:

[0249] Preparation ofN-3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine,N-(3-methylbutyl)-N-(t-butyloxycarbonyl). A solution of 16.7 g (28.0mmol) of product from Part C in 250 mL of methanol was hydrogenated over6.0 g of 10% palladium-on-carbon and under 50 psig hydrogen for onehour. The catalyst was filtered and the solution concentrated to afford10.0 g of free amine. This was dissolved in 100 mL of methylenechloride, 4.35 g (43 mmol) of N-methylmorpholine was added followed by5.53 g (20.5 mmol) of quinoline-2-carboxylic acid, N-hydroxysuccinimideester. This was stirred at room temperature overnight, the solventremoved, ethyl acetate added and washed with 5% citric acid, sat'dsodium bicarbonate, brine, dried and concentrated to afford 14 g ofcrude product. Recrystallization from ethyl acetate and hexane afforded10.5 g (83%) of desired product.

[0250] Part E:

[0251] Preparation ofN-3(S)-[N-(2-quinolinyl-carbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine,N-(3-methylbutyl). To 80 mL of 4N hydrochloric acid in dioxane was added9.17 g (14.8 mmol) of product from Part D above. After one hour theproduct becomes gummy. The solvents were removed, diethyl ether addedand removed and the residue dissolved in 20 mL of methanol. Thissolution was added to 400 mL of sat'd aqueous sodium bicarbonate, thesolids collected, washed with acetone and hexane and dried in vacuo overP₂O₅ to afford 4.75 g of the desired product.

[0252] Part F:

[0253] To a solution of 200 mg (0.3w mmol) of the amino alcohol fromPart E above in 10 mL of anhydrons tetrahydrofuran and 0.3 ML ofN,N-dimethylformamide, was added 42 mg (0.42 mmol) of triethylamine andthen 55 mg (0.38 mmol) of dimethylsulfamoyl chloride. After stirringfrom twenty hours at room temperature, the volatiles were removed invacuo, ethyl acetate added and the solution washed with 5% aqueouscitric acid, saturated aqueous sodium bicarbonate and saturated brine.The organic layer was dried and concentrated to afford 166 mg of crudeproduct, which was chromatographed on silica gel using a gradient of1-10% isopropanol in methylene chloride to afford 119 mg of pureproduct, is m/e 627 (M+H). Calcd. for C₃₁H₄₂N₆O₆S 627.2965, found627.2998.

EXAMPLE 19

[0254]

[0255] Preparation of[(4-methoxyphenyl)methyl][3-[[3-[[[(1.1-dimethylethyl)aminolsulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]amino]-2R-methyl-3-oxopropyl]carbamate

[0256] To a solution of 83 mg (0.31 mmol) ofN-(4-methoxy)benzyloxycarbonyl 2R-methyl-3-aminopropionic acid and 71 mg(0.46 mmol) c-f N-hydroxybenzozriazole in 2 mL 301 of anhydrousN,N-dimethylformamide (DMF) at 0° C., was added 65 mg (0.34 mmol) of1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After twohours at 0° C., a solution of 104 mg (0.28 mmol) of free amine fromexample 8, part C in 0.5 mL of DMF was added. After two hours at 0° C.and fourteen hours at room temperature, the DMF was removed in vacuo,ethyl acetate added, washed with saturated aqueous sodium bicarbonate,brine, dried over anhydrous magnesium sulfate, filtered and concentratedto afford 200 mg of crude materal. This was chromatographed on silicagel using 3% methanol/methylene chloride to afford 120 mg of product,which was further purified by crystallization from diethyl ether/hexaneto afford 25 mg (13%) of the desired product m/e=627 (M+Li).

EXAMPLE 20

[0257]

[0258] Preparation ofN4-[3-[[[(1.1-dimerhylethyl)aminol-sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)-amino]butanediamide

[0259] 107 mg (0.37 mmol) of N-2—(quinoylcarbonyl)-L-isoasparagine and76 ma (1.5 ea) of N-hydroxysuccinamide were dissolved in 2 mL ofdimethylformamide and cooled to zero degrees C. To this was added 111 mg(0.37 mmol) of EDC and the solution stirred for 20 minutes. To thiscooled solution was added 140 mg 18.37 moll) of the free amine fromexample 8, part C and the reaction was returned to room temperature andstirred for 18 hours. The dimethylformamide was removed by evaporationand the residue was partitioned between ethyl acetate and saturatedsodium bicarbonate. The organic layer was washed with 5% KHSO₄ andbrine, dried over magnesium sulfate, filtered and concentrated to yield216 mg of crude solid, which was chromatographed using ethylacetate:methanol:hexane, 95:5:50 to yield 110 mg (4.8% yield) of pureproduct, m/e=641 (M+H).

EXAMPLE 21

[0260] Following the procedures of Examples 1-20, the compounds shown inTables 3A and 3B were prepared. TABLE 3A

Entry No. R R¹ R³ R⁴ R⁵ 1 Cbz t-Butyl i-Amyl Methyl Methyl 2 Q t-Butyli-Amyl Methyl Methyl 3 Cbz i-Butyl i-Butyl Methyl Hydrogen 4 N,N-t-Butyl i-Butyl n-Butyl Hydrogen Dimethyl- glycine 5 N,N- t-Butyli-Butyl Methyl Hydrogen Dimethyl- glycine 6 Q CH₂C(O)NH₂ i-Butyl n-ButylHydrogen 7 Q CH₂C(O)NH₂ i-Butyl t-Butyl Hydrogen 8 Q CH₂C(O)NH₂ i-Butyl

9 Q CH₂C(O)NH₂ i-Butyl Phenyl Hydrogen 10 Q CH₂C(O)NH₂ i-ButylCyclohexyl Hydrogen

[0261] TABLE 3B

Entry R R¹ R³ R⁴ R⁵ A Cbz t-butyl isoamyl methyl methyl B Cbz t-butylisobutyl methyl H C N,N-Dimethyl- t-butyl isobutyl methyl H glycine D QCH₂CONH₂ isobutyl cyclohexyl H E Q CH₂CONH₂ isobutyl phenyl H FN,N-Dimethyl- glycine t-butyl isobutyl

[0262] Utilizing the procedures set forth above, the compounds shown inTables 4-14 could be prepared. Thus, utilizing the intermediates ofExamples 1-10 according to the procedures in Examples 14-21, thecompounds shown in Tables 4-16 could be prepared. TABLE 4

Entry No. R R³ R⁴ R⁵ 1 Cbz^(a) CH₃ n-Butyl CH₃ 2 Cbz i-Butyl CH₃ C₆H₅ 3Cbz i-Butyl n-Butyl H 4 Q^(b) i-Butyl n-Butyl H 5 Cbz i-Propyl n-Butyl H6 Q i-Propyl n-Butyl CH₃ 7 Cbz C₆H₅ n-Butyl H 8 Cbz

n-Butyl H 9 Cbz

n-Butyl H 10 Q

n-Butyl H 11 Cbz

n-Butyl H 12 Cbz i-Butyl n-Propyl H 13 Cbz i-Butyl —CH₂CH(CH₃)₂ H 14 Cbz

n-Butyl H 15 Cbz

i-Propyl H 16 Cbz

—CH₂CH₂CH(CH₃)₂ H 17 Cbz i-Butyl —CH₂CH₃ H 13 Cbz i-Butyl —CH(CH₃)₂ H 19Cbz i-Butyl

H 20 Q n-Butyl

H 21 Cbz

—(CH₂)₂CH(CH₃)₂ H 22 Cbz (CH₂)₂CH(CH₃)₂ —CH(CH₃)₂ H 23 Q i-Butyl—CH(CH₃)₂ H 24 Cbz i-Butyl —C(CH₃)₃ H 25 Q i-Butyl —C(CH₃)₃ H 26 Cbz

—C(CH₃)₃ H 27 Q

—C(CH₃)₃ H 28 Cbz —(CH₂)₂CH(CH₃)₂ —C(CH₃)₃ CH₃ 29 Q —(CH₂)₂CH(CH₃)₂—C(CH₃)₃ CH₃ 30 Cbz —CH₂C6H₅ —C(CH₃)₃ H 31 Q —CH₂C₆H₅ —C(CH₃)₃ H 32 Cbz—(CH₂)₂C₆H₅ —C(CH₃)₃ CH₃ 33 Cbz —(CH₂)₂C₆H₅ —C(CH₃)₃ H 34 Cbz n-Butyl—C(CH₃)₃ H 35 Cbz n-Pentyl —C(CH₃)₃ H 36 Cbz n-Hexyl —C(CH₃)₃ H 37 Cbz

—C(CH₃)₃ H 38 Cbz —CH₂C(CH₃)₃ —C(CH₃)₃ H 39 Q —CH₂C(CH₃)₃ —C(CH₃)₃ H 40Cbz

—C(CH₃)₃ H 41 Cbz —CH₂C₆H₅OCH₃(para) —C(CH₃)₃ H 42 Cbz

—C(CH₃)₃ H 43 Cbz

—C(CH₃)₃ H 44 Cbz —(CH₂)₂C(CH₃)₃ —C(CH₃)₃ H 45 Q —(CH₂)₂C(CH₃)₃ —C(CH₃)₃H 46 Cbz —(CH₂)₄OH —C(CH₃)₃ H 47 Q —(CH₂)₄OH —C(CH₃)₃ H 48 Q

—C(CH₃)₃ H 49 Q

—C(CH₃)₃ H 50 Cbz —CH₂CH(CH₃)₂ —C₆H₅ H 51

—CH₂CH(CH₃)₂ —C₆H₅ Me 52

—CH₂CH(CH₃)₂ —C₆H₅ H 53

—CH₂CH(CH₃)₂ —C₆H₅ H 54

—CH₂CH(CH₃)₂ —C₆H₅ H 55

—CH₂CH(CH₃)₂ —C₆H₅ Me 56

—CH₂CH(CH₃)₂ —C₆H₅ H 57

—CH₂CH(CH₃)₂ —C₆H₅ Me 58

—CH₂CH(CH₃)₂ —C₆H₅ Me 59

—CH₂CH(CH₃)₂ —C₆H₅ H 60

—CH₂CH(CH₃)₂ —C₆H₅ Me 61

—CH₂CH(CH₃)₂ —C₆H₅ H 62

—CH₂CH(CH₃)₂ —C₆H₅ H 63

—CH₂CH(CH₃)₂ —C₆H₅ H 64

—CH₂CH(CH₃)₂ —C₆H₅ Me 65

—CH₂CH(CH₃)₂ —C₆H₅ H 66

—CH₂CH(CH₃)₂ —C₆H₅ H 67

—CH₂CH(CH₃)₂ —C₆H₅ H 68

—CH₂CH(CH₃)₂ —C₆H₅ H 69

—CH₂CH(CH₃)₂ —C₆H₅ H 70 Q —CH₂Ph -Ph H 71 Q

-Ph H 72 Q

-Ph H 73 Q

-Ph H 74 Q

-Ph H 75 Q

-Ph H 76 Q —CH₂CH═CH₂ -Ph H 77 Q

-Ph H 78 Q

-Ph H 79 Q —CH₂CH₂Ph -Ph H 80 Q —CH₂CH₂CH₂CH₂OH -Ph H 81 Q—CH₂CH₂N(CH₃)₂ -Ph H 82 Q

-Ph H 83 Q —CH₃ -Ph H 84 Q —CH₂CH₂CH₂SCH₃ -Ph H 85 Q —CH₂CH₂CH₂S(O)₂CH₃-Ph H 86 Q —CH₂CH₂CH₂CH(CH₃)₂

H 87 Q —CH₂CH₂CH(CH₃)₂

H 88 Q —CH₂CH₂CH(CH₃)₂ —CH₂CH₂CH₃ H 89 Q —CH₂CH₂CH₂CH(CH₃)₂ —CH₃ H 90 Q—CH₂CH₂CH(CH₃)₂

H 91 Q —CH₂CH₂CH(CH₃)₂

H 92 Q —CH₂CH₂CH(CH₃)₂

H 93 Q —CH₂CH₂CH(CH₃)₂

H 94 Q —CH₂CH₂CH(CH₃)₂

H 95 Q —CH₂CH₂CH(CH₃)₂

H 96 Q —CH₂CH₂CH(CH₃)₂

H 97 Q —CH₂CH₂CH(CH₃)₂

H 98 Q —CH₂CH₂CH(CH₃)₂

H 99 Q —CH₂CH₂CH(CH₃)₂

H 100 Q —CH₂CH₂CH(CH₃)₂

H 101 Q —CH₂CH₂CH(CH₃)₂

102 Q —CH₂CH₂CH(CH₃)₂

H 103 Q —CH₂CH(CH₃)₂

H 104 Q —CH₂CH(CH₃)₂

H 105 Q —CH₂CH(CH₃)₂

H 106 Q —CH₂CH₂CH₃

H 107 Q —CH₂CH₂CH₂CH₃

H 108 Q —CH₂CH₂CH₃

H 109 Q —CH₂CH₂CH₃

H 110 Q —CH₂CH₂CH₃

H 111 Q —CH₂CH₂CH₃

H

[0263] TABLE 5

Entry No. A R³ R⁴ 1 Cbz-Val i-amyl —C₆H₅ 2 Cbz-Leu i-amyl —C₆H₅ 3Cbz-Ile i-amyl —C₆H₅ 4 Ac-D-homo-Phe i-Bu methyl 5 Qui-Orn(g-Cbz)

—C₆H₅ 6 Cbz-Asn —CH₂CH═CH₂ —C₆H₅ 7 Acetyl-t-BuGly i-amyl —C₆H₅ 8Acetyl-Phe i-amyl —C₆H₅ 9 Acetyl-Ile i-amyl —C₆H₅ 10 Acetyl-Leu i-amyl—C₆H₅ 11 Acetyl-His i-amyl —C₆H₅ 12 Acetyl-Thr i-amyl —C₆H₅ 13Acetyl-NHCH(C(CH₃)₂(SCH₃))C(O)— i-amyl —C₆H₅ 14 Cbz-Asn i-amyl —C₆H₅ 15Cbz-Ala i-amyl —C₆H₅ 16 (N,N-dimethylglycinyl)Val i-amyl —C₆H₅ 17(N-methylglycinyl)Val i-amyl —C₆H₅ 18 (N,N-dimethylglycinyl)Ile i-amyl—C₆H₅ 19 (N-methylglycinyl)Ile i-amyl —C₆H₅ 20 (N,N-dimethylglycinyl)Vali-butyl n-butyl 21 (N,N-dimethylglycinyl)Val i-amyl n-butyl 22(N,N-dimethylglycinyl)Val

n-butyl 23 (N,N-dimethylglycinyl)Val

n-butyl 24 (N,N-dimethylglycinyl)Ile i-butyl n-butyl 25(N,N-dimethylglycinyl)Ile i-amyl n-butyl 26 (N,N-dimethylglycinyl)Ile

n-butyl 27 (N,N-dimethylglycinyl)Ile

n-butyl 20 Cbz-Ala i-amyl —C₆H₅ 21 Cbz-beta-cyanoAla i-amyl —C₆H₅ 22Cbz-t-BuGly i-amyl —C₆H₅ 23 Q-t-BuGly i-amyl —C₆H₅ 24 Q-SCH₃Cys i-amyl—C₆H₅ 25 Cbz-SCH₃Cys i-amyl —C₆H₅ 26 Q-Asp i-amyl —C₆H₅ 27Cbz-(NHCH(C(CH₃)₂(SCH₃))C(O)— i-amyl —C₆H₅ 28 Cbz-EtGly i-amyl —C₆H₅ 29Cbz-PrGly i-amyl —C₆H₅ 30 Cbz-Thr i-amyl —C₆H₅ 31 Q-Phe i-amyl —C₆H₅ 32Cbz-Phe i-amyl —C₆H₅ 33 (N,N-dimethylglycinyl)Val i-butyl t-butyl 34(N,N-dimethylglycinyl)Val i-amyl t-butyl 35 (N,N-dimethylglycinyl)Val

t-butyl 36 (N,N-dimethylglycinyl)Val

t-butyl 37 (N,N-dimethylglycinyl)Ile i-butyl t-butyl 38(N,N-dimethylglycinyl)Ile i-amyl t-butyl 39 (N,N-dimethylglycinyl)Ile

t-butyl 40 (N,N-dimethylglycinyl)Ile

t-butyl

[0264] TABLE 6

Entry R¹ R⁴ 1 CH₂SO₂CH₃ t-butyl 2 (R)—CH(OH)CH₃ t-butyl 3 CH(CH₃)₂t-butyl 4 (R,S)CH₂SOCH₃ t-butyl 5 CH₂SO₂NH₂ t-butyl 6 CH₂SCH₃ t-butyl 7CH₂CH(CH₃)₂ t-butyl 8 CH₂CH₂C(O)NH₂ t-butyl 9 (S)—CH(OH)CH₃ t-butyl 10—CH₂C≡C—H t-butyl

[0265] TABLE 7

Entry R² A R⁴ 1 n-Bu Cbz-Asn t-butyl 2 cyclohexylmethyl Cbz-Asn t-butyl3 n-Bu Boc t-butyl 4 n-Bu Cbz t-butyl 5 C₆H₅CH₂ Boc t-butyl 6P—F—C₆H₅CH₂ Cbz t-butyl 7 C₆H₅CH₂ benzoyl t-butyl 8 cyclohexylmethyl Cbzt-butyl 9 n-Bu Q-Asn t-butyl 10 cyclohexylmethyl Q-Asn t-butyl 11C₆H₅CH₂ Cbz-Ile t-butyl 12 C₆H₅CH₂ Q-Ile t-butyl 13 P—F—C₆H₅CH₂Cbz-t-BuGly t-butyl 14 C₆H₅CH₂ Q-t-BuGly t-butyl 15 C₆H₅CH₂ Cbz-Valt-butyl 16 C₆H₅CH₂ Q-Val t-butyl 17 2-naphthylmethyl Cbz-Asn t-butyl 182-naphthylmethyl Q-Asn t-butyl 19 2-naphthylmethyl Cbz t-butyl 20 n-BuCbz-Val t-butyl 21 n-Bu Q-Val t-butyl 22 n-Bu Q-Ile t-butyl 23 n-BuCbz-t-BuGly t-butyl 24 n-Bu Q-t-BuGly t-butyl 25 p-F(C₆H₄)CH₂ Q-Asnt-butyl 26 p-F(C₆H₄)CH₂ Cbz t-butyl 27 p-F(C₆H₄)CH₂ Cbz-Asn t-butyl 28C₆H₅CH₂ Cbz-propargylglycine t-butyl 29 C₆H₅CH₂ Q-propargylglycinet-butyl 30 C₆H₅CH₂ acetylpropargylglycine t-butyl

[0266] TABLE 8

Entry R³ R⁴ 1 —CH₂CH(CH₃)₂ —C(CH₃)₂ 2 —CH₂CH₂CH(CH₃)₂

3 —CH₂CH₂CH(CH₃)₂

4 —CH₂CH₂CH(CH₃)₂

5 —CH₂CH₂CH(CH₃)₂

[0267] TABLE 9

Entry R R¹ 1

—CH₃ 2

—CH₃ 3

—CH(CH₃)₂ 4

—CH(CH₃)₂ 5

—C(CH₃)₃ 6

—CH₃ 7

—CH₃ 8

—CH₃ 9

—CH₃ 10

—CH₃ 11

—CH₃ 12

—CH₃ 13

—CH₃ 14

—CH₃ 15

—CH₃ 16

—CH₃ 17

—CH₃ 18

19

[0268] TABLE 10

Entry R¹ R^(1′) R^(1″) R 1 H H H

2 H H H

3 H CH₃ H

4 H CH₃ CH₃

5 H H CO₂CH₃

6 H H H

7 H H H

8 H H CONH₂ Cbz 9 H H CONH₂ 2-quinolinylcarbonyl

[0269] TABLE 11

Entry R R′ X 1 R = H R′ = H X = H 2 R = Me R′ = Me X = H 3 R = H R′ = MeX = H 4 R = Me R′ = Me X = F 5 R = H R′ = Me X = F 6 R = Cbz R′ = Me X =H 7 R = H R′ = Bz X = H 8 R + R′ = pyrrole X = H

[0270] TABLE 12

Entry Acyl Group (R) 1 benzyloxycarbonyl 2 tert-butoxycarbonyl 3 acetyl4 2-quinoylcarbonyl 5 phenoxyacetyl 6 benzoyl 7 methyloxaloyl 8 pivaloyl9 trifluoracetyl 10 bromoacetyl 11 hydroxyacetyl 12 morpholinylacetyl 13N,N-dimethylaminoacetyl 14 N-benzylaminoacetyl 15 N-phenylaminoacetyl 16N-benzyl-N-methylaminoacetyl 17 N-methyl-N-(2-hydroxyethyl)aminoacetyl18 N-methylcarbamoyl 19 3-methylbutyryl 20 N-isobutylcarbamoyl 21succinoyl (3-carboxypropionyl) 22 carbamoyl 23 N-(2-indanyl)aminoacetyl24 N-methylaminoacetyl

[0271] TABLE 13

Entry R³ R⁴ 1 —CH₃ -n-Butyl 2 -n-Butyl —CH₃ 3 -i-Butyl -n-Butyl 4-i-Propyl -n-Butyl 5 —C₆H₅ -n-Butyl 6

-n-Butyl 7

-n-Butyl 8

-n-Butyl 9 -i-Butyl -n-Propyl 10 -i-Butyl —CH₂CH(CH₃)₂ 11

-n-Butyl 12

-i-Propyl 13

—CH₂CH₂CH(CH₃)₂ 14 i-Butyl —CH₂CH₃ 15 i-Butyl —CH(CH₃)₂ 16 i-Butyl

17

—(CH₂)₂CH(CH₃)₂ 18 (CH₂)₂CH(CH₃)₂ —CH(CH₃)₂ 19 i-Butyl —CH(CH₃)₂ 20i-Butyl —C(CH₃)₃ 21

—C(CH₃)₃ 22 —(CH₂)₂CH(CH₃)₂ —C(CH₃)₃ 23 —CH₂C₆H₅ —C(CH₃)₃ 24 —(CH₂)₂C₆H₅—C(CH₃)₃ 25 n-Butyl —C(CH₃)₃ 26 n-Pentyl —C(CH₃)₃ 27 n-Hexyl —C(CH₃)₃ 28

—C(CH₃)₃ 29 —CH₂C(CH₃)₃ —C(CH₃)₃ 30

—C(CH₃)₃ 31 —CH₂C₆H₅OCH₃ (para) —C(CH₃)₂ 32

—C(CH₃)₃ 33

—C(CH₃)₃ 34 —(CH₂)₂C(CH₃)₃ —C(CH₃)₃ 35 —(CH₂)₄OH —C(CH₃)₃ 36

—C(CH₃)₃ 37

—C(CH₃)₃ 38 —CH₂CH(CH₃)₂ —C₆H₅ 39 i-amyl —CH₂C(CH₃)₃ 40

—CH₂C(CH₃)₃ 41

—CH₂C(CH₃)₃ 42 i-butyl —CH₂C(CH₃)₃ 43 —CH₂Ph -Ph 44

-Ph 45

-Ph 46

-Ph 47

-Ph 48

-Ph 49 —CH₂CH═CH₂ -Ph 50

-Ph 51

-Ph 52 —CH₂CH₂Ph -Ph 53 —CH₂CH₂CH₂CH₂OH -Ph 54 —CH₂CH₂N(CH₃)₂ -Ph 55

-Ph 56 —CH₃ -Ph 57 —CH₂CH₂CH₂SCH₃ -Ph 58 —CH₂CH₂CH₂S(O)₂CH₃ -Ph 59—CH₂CH₂CH(CH₃)₂

60 —CH₂CH₂CH(CH₃)₂

61 —CH₂CH₂CH(CH₃)₂ —CH₂CH₂CH₃ 62 —CH₂CH₂CH(CH₃)₂ —CH₃ 63 —CH₂CH₂CH(CH₃)₂

64 —CH₂CH₂CH(CH₃)₂

65 —CH₂CH₂CH(CH₃)₂

66 —CH₂CH₂CH(CH₃)₂

67 —CH₂CH₂CH(CH₃)₂

68 —CH₂CH₂CH(CH₃)₂

69 —CH₂CH₂CH(CH₃)₂

70 —CH₂CH₂CH(CH₃)₂

71 —CH₂CH₂CH(CH₃)₂

72 —CH₂CH₂CH(CH₃)₂

73 —CH₂CH₂CH(CH₃)₂

74 —CH₂CH₂CH(CH₃)₂

75 —CH₂CH(CH₃)₂

76 —CH₂CH(CH₃)₂

77 —CH₂CH(CH₃)₂

78 —CH₂CH(CH₃)₂

79 —CH₂CH₂CH₃

80 —CH₂CH₂CH₂CH₃

81 i-butyl t-butyl 82 i-amyl t-butyl 83

t-butyl 84

t-butyl 85 i-butyl

[0272] TABLE 14

Entry R¹ R³ 1 C(CH₃)₃ CH₂CH₂CH(CH₃)₂ 2 CH₂C≡CH CH₂CH₂CH(CH₃)₂ 3C(CH₃)₂(SCH₃) CH₂CH₂CH(CH₃)₂ 4 C(CH₃)₂(S[O]CH₃) CH₂CH₂CH(CH₃)₂ 5C(CH₃)₂(S[O]₂CH₃) CH₂CH₂CH(CH₃)₂ 6 C(CH₃)₃ CH₂CH(CH₃)₂ 7 C(CH₃)₃

8 CH(CH₃)₂ CH₂CH(CH₃)₂ 9 CH(CH₂CH₃)(CH₃) CH₂CH(CH₃)₂

[0273] TABLE 15

R₃

—CH₂CH(CH₃)₂ —N(CH₃)₂ —CH₂CH(CH₃)₂ —N(CH₂CH₃)₂ —CH₂CH(CH₃)₂—N(CH(CH₃)₂)₂ —CH₂CH₂CH(CH₃)₂ —N(CH₃)₂ —CH₂CH₂CH(CH₃)₂ —N(CH₂CH₃)₂—CH₂CH₂CH(CH₃)₂

—N(CH₃)₂—N(CH₂CH₃)₂ —CH₂CH₂CH(CH₃)₂

—CH₂CH₂CH(CH₃)₂

N(CH₃)(t-Bu)

—CH₂CH(CH₃)₂

—CH₂CH(CH₃)₂

—CH₂CH(CH₃)₂

[0274] TABLE 16

R₃

—CH₂CH(CH₃)₂ —N(CH₃)₂ —CH₂CH(CH₃)₂ —N(CH₂CH₃)₂ —CH₂CH(CH₃)₂—N(CH(CH₃)₂)₂ —CH₂CH₂CH(CH₃)₂ —N(CH₃)₂ —CH₂CH₂CH(CH₃)₂ —N(CH₂CH₃)₂—CH₂CH₂CH(CH₃)₂

—N(CH₃)₂—N(CH₂CH₃)₂

N(CH₃)(t-Bu)

—CH₂CH(CH₃)₂

—CH₂CH(CH₃)₂

—CH₂CH(CH₃)₂

[0275] Example 22

[0276] The compounds of the present invention are effective HIV proteaseinhibitors. Utilizing an enzyme assay as described below, the compoundsset forth in the examples herein disclosed inhibited the HIV enzyme. Thepreferred compounds of the present invention and their calculated IC50(inhibiting concentration 50%, i.e., the concentration at which theinhibitor compound reduces enzyme activity by 50%) values are shown intable 17. The enzyme method is described below. The substrate is2-Ile-Nle-Phe(p-NO₂)-Gin-ArgNH₂. The positive control is MVT-101(Miller, f et al, Science, 246, 1149 (1989)] The assay conditions are asfollows:

[0277] Assay buffer:

[0278] 20 mM sodium phosphate, pH 6.4

[0279] 20% glycerol

[0280] 1 mM EDTA

[0281] 1 mM DTT

[0282] 0.1% CHAPS

[0283] The above described substrate is dissolved in DMSO, then diluted10 fold in assay buffer. Final substrate concentration in the assay is80 μM.

[0284] HIV protease is diluted in the assay buffer to a final enzymeconcentration of 12.3 nanomolar, based on a molecular weight of 10,780.

[0285] The final concentration of DMSO is 14% and the finalconcentration of glycerol is 18%. The test compound is dissolved in DMSOand diluted in DMSO to 10× the test concentration; 10 μl of the enzymepreparation is added, he materials mixed and then the mixture isincubated at ambient temperature for 15 minutes. The enzyme reaction isinitiated by the addition c: 40 μl of substrate. The increase influorescence is monitored at 4 time points (0, 8, 16 and 24 minutes) atambient temperature. Each assay is carried out in duplicate wells.

[0286] The preceding examples can be repeated with similar success bysubstituting the generically or specifically described reactants and/oroperating conditions of this invention for those used in the precedingexamples. TABLE 17 Entry Compound IC₅₀(nanomolar) 1

40 2

5 3

3 4

2 5

13

EXAMPLE 23

[0287] The effectiveness of the compounds listed in Table 17 weredetermined in the above-described enzyme assay and in a CEM cell assay.

[0288] The HIV inhibition assay method of acutely infected cells is anautomated tetrazolium based calorimetric assay essentially that reportedby Pauwles et al, J. Virol. Methods, 20, 309-321 (1988). Assays wereperformed in 96-well tissue culture plates. CEM cells, a CD4⁺ cell line,were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetalcalf serum and were then treated with polybrene (2 μg/ml. An 80 μlvolume of medium containing 1×10⁴ cells was dispensed into each well ofthe tissue culture plate. To each well was added a 100 μl volume of testcompound dissolved in tissue culture medium (or medium without testcompound as a control to achieve the desired final concentration and thecells were incubated at 37° C. for 1 hour. A frozen culture co HIV-1Lwas diluted in culture medium co a concentration of 5×10⁴ TCID₅₀ per ml(TCID₅₀=the dose of virus chat infects 50% of cells in tissue culture)and a 20 μL volume of the virus sample (containing 1000 TCID₅₀ of virus)was added to wells containing test compound and to wells containing onlymedium (infected control cells). Several wells received culture mediumwithout virus (uninfected control cells). Likewise, the intrinsictoxicity of the test compound was determined by adding medium withoutvirus to several wells containing test compound in summary, the tissueculture plates contained the following experiments: Virus CellsDrug 1. + − − 2. + + − 3. + − + 4. + + +

[0289] In experiments 2 and 4 the final concentrations of test compoundswere 1, 10, 100 and 500 μg/ml. Either azidothymidine (AZT) ordideoxyinosine (ddI) was included as a positive drug control. Testcompounds were dissolved in DMSO and diluted into tissue culture mediumso that the final DMSO concentration did not exceed 1.5% in any case.DMSO was added to all control wells at an appropriate concentration.

[0290] Following the addition of virus, cells were incubated at 37° C.in a humidified, 5% CO₂ atmosphere for 7 days. Nest compounds could beadded on days 0, 2 and 5 if desired. On day 7, post-infection, the cellsin each well were resuspended and a 100 μl sample of each cellsuspension was removed for assay. A 20 μL volume of a 5 mg/ml solutionof 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)was added to each 100 μL cell suspension, and the cells were incubatedfor 4 hours at 270C in a 5% CO₂ environment. During this incubation, MTTis metabolically reduced by living cells resulting in the production inthe cell of a colored formazan product. To each sample was added 100 μlof 10% sodium dodecylsulfate in 0.01 N HCl to lyse the cells, andsamples were incubated overnight. The absorbance at 590 nm wasdetermined for each sample using a Molecular Devices microplate reader.Absorbance values for each set of wells is compared to assess viralcontrol infection, uninfected control cell response as well as testcompound by cytotoxicity and antiviral efficacy.

[0291] The biological data shown in Tables 18 and 19 were obtained fromthe compounds shown in Tables 1C and 3B, respectively. TABLE 18 EntryIC₅₀ or Table 1c % Inhibition EC₅₀ TD₅₀ A 29% @ 0.1 uM B 55% @ 10.0 uM C59% @ 1.0 uM D 29% @ 0.1 uM E 70 nM 880 nM 7.5 uM F 22% @ 0.1 uM G 66 nMH 48% @ 10.0 uM I 1.7 uM J 2.69 uM K 60% @ 1.0 uM L 38% @ 10.0 uM

[0292] TABLE 19 Entry Table 3B IC₅₀ (nM) EC₅₀ (nM) TD₅₀ (μM) A 20 B 27 C42 350 >100 D 4.4 27 289 E 4.0 13 8.3 F 6.6 17 77

[0293] TABLE 20 Entry Compound IC₅₀ (nm) EC₅₀ (nm) TD₅₀ (nm) 1

40  167 56,000 2

5  23 65,000 3

3  42 28,000 4

2 <15 39,000

[0294] The compounds of the present invention are effective antiviralcompounds and, in particular, are effective retroviral inhibitors asshown above. Thus, the subject compounds are effective HIV proteaseinhibitors. It is contemplated that the subject compounds will alsoinhibit other retroviruses such as other lentiviruses in particularother strains of HIV, e.g. HIV-2, human T-cell leukemia virus,respiratory syncitial virus, simia immunodeficiency virus, felineleukemia virus, feline immuno-deficiency virus, hepadnavirus,cytomegalovirus and picornavirus. Thus, the subject compounds areeffective in the treatment and/or proplylaxis of retroviral infections.

[0295] Compounds of the present invention can possess one or moreasymmetric carbon atoms and are thus capable of existing in the form ofoptical isomers as well as in the form of racemic or nonracemic mixturesthereof. The optical isomers can be obtained by resolution of theracemic mixtures according to conventional processes, for example byformation of diastereoisomeric salts by treatment with an opticallyactive acid or base. Examples of appropriate acids are tartaric,diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric andcamphorsulfonic acid and then separation of the mixture ofdiastereoisomers by crystallization followed by liberation of theoptically active bases from these salts. A different process forseparation of optical isomers involves the use of a chiralchromatography column optimally chosen co maximize the separation of theenantiomers. Still another available method involves synthesis ofcovalent diastereoisomeric molecules by reacting compounds of Formula Iwith an optically pure acid in an activated form or an optically pureisocyanate. The synthesized diastereoisomers can be separated byconventional means such as chromatography, distillation, crystallizationor sublimation, and then hydrolyzed to deliver the enantiomerically purecompound. The optically active compounds of Formula I can likewise beobtained by utilizing optically active starting materials. These isomersmay be in the form of a free acid, a free base, an ester or a salt.

[0296] The compounds of the present invention can be used in the form ofsalts derived from inorganic or organic acids. These salts include butare not limited to the following: acetate, adipate, alginate, citrate,aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate,camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate,ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate,heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide,hydroiodide, 2-hydroxy-echanesulfonate, lactate, maleate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate,pectinate, persulfate, 3-phenylpro-pionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, tosylate, mesylate andundecanoate. Also, the basic nitrogen-containing groups can bequaternized with such agents as lower alkyl halides, such as methyl,ethyl, propyl, and butyl chloride, bromides, and iodides; dialkylsulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, longchain halides such as decyl, lauryl, myristyl and stearyl chlorides,bromides and iodides, aralkyl halides like benzyl and phenethylbromides, and others. Water or oil-soluble or dispersible products arethereby obtained.

[0297] Examples of acids which may be employed to form pharmaceuticallyacceptable acid addition salts include such inorganic acids ashydrochloric acid, sulphuric acid and phosphoric acid and such organicacids as oxalic acid, maleic acid, succinic acid and citric acid. Otherexamples include salts with alkali metals or alkaline earth metals, suchas sodium, potassium, calcium or magnesium or with organic bases.

[0298] Total daily dose administered to a host in single or divideddoses may be in amounts, for example, from 0.001 to 50 mg/kg body weightdaily and more usually 0.01 to 1 mg. Dosage unit compositions maycontain such amounts of submultiples thereof to make up the daily dose.

[0299] The amount of active ingredient that may be combined with thecarrier materials to produce a single dosage form will vary dependingupon the host treated and the particular mode of administration.

[0300] The dosage regimen for treating a disease condition with thecompounds and/or compositions of this invention is selected inaccordance with a variety of factors, including the type, age, weight,sex, diet and medical condition of the patient, the severity of thedisease, the route of administration, pharmacological considerationssuch as the activity, efficacy, pharmacokinetic and toxicology profilesof the particular compound employed, whether a drug delivery system isutilized and whether the compound is administered as part of a drugcombination. Thus, the dosage regimen actually employed may vary widelyand therefore may deviate from the preferred dosage regimen set forthabove.

[0301] The compounds of the present invention may be administeredorally, parenterally, by inhalation spray, rectally, or topically indosage unit formulations containing conventional nontoxicpharmaceutically acceptable carriers, adjuvants, and vehicles asdesired. Topical administration may also involve the use of transdermaladministration such as transdermal patches or iontophoresis devices. Theterm parenteral as used herein includes subcutaneous injections,intravenous, intramuscular, intrasternal injection, or infusiontechniques.

[0302] Injectable preparations, for example, sterile injectable aqueousor oleaginous suspensions may be Formulated according to the known artusing suitable Dispersing or wetting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectable solutionor suspension in a nontoxic parenterally acceptable diluent or solvent,for example, as a solution in 1,3-butanediol. Among the acceptablevehicles and solvents that may be employed are water, Ringer's solution,and isotonic sodium chloride solution. In addition, sterile, fixed oilsare conventionally employed as a solvent or suspending medium. For thispurpose any bland fixed oil may be employed including synthetic mono- ordiglycerides. In addition, fatty acids such as oleic acid find use inthe preparation of injectables.

[0303] Suppositories for rectal administration of the drug can beprepared by mixing the drug with a suitable nonirritating excipient suchas cocoa butter and polyethylene glycols which are solid at ordinarytemperatures but liquid at the rectal temperature and will thereforemelt in the rectum and release the drug.

[0304] Solid dosage forms for oral administration may include capsules,tablets, pills, powders, and granules. In such solid dosage forms, theactive compound may be admixed with at least one inert diluent such assucrose lactose or starch. Such dosage forms may also comprise, as innormal practice, additional substances other than inert diluents, e.g.,lubricating agents such as magnesium stearate. In the case of capsules,tablets, and pills, the dosage forms may also comprise buffering agents.Tablets and pills can additionally be prepared with enteric coatings.

[0305] Liquid dosage forms for oral administration may includepharmaceutically acceptable emulsions, solutions, suspensions, syrups,and elixirs containing inert diluents commonly used in the art, such aswater. Such compositions may also comprise adjuvants, such as wettingagents, emulsifying and suspending agents, and sweetening, flavoring,and perfuming agents.

[0306] While the compounds of the invention can be administered as thesole active pharmaceutical agent, they can also be used in combinationwith one or more immunomodulators, antiviral agents or otherantiinfective agents. For example, the compounds of the invention can beadministered in combination with AZT, DDI, DDC or with glucosidaseinhibitors, such as N-butyl-1-deoxynojirimycin or prodrugs thereof, forthe prophylaxis and/or treatment of AIDS. When administered as acombination, the therapeutic agents can be formulated as separatecompositions which are given at the same time or different times, or thetherapeutic agents can be given as a single composition.

[0307] The foregoing is merely illustrative of the invention and is notintended to limit the invention to the disclosed compounds. Variationsand changes which are obvious to one skilled in the art are intended tobe within the scope and nature of the invention which are defined in theappended claims.

[0308] From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions.

What is claimed is:
 1. A compound represented by the formula:

or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,aralkyl, alkoxycarbonyl, aryloxyalkyl, heteroaryloxyalkyl,aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, alkoxyalkyl, hydroxyalkyl,aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyland mono- and disubstituted aminoalkanoyl radicals wherein thesubstituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or wherein said aminocarbonyl andaminoalkanoyl radicals are disubstituted, said substituents along withthe nitrogen atom to which they are attached form a heterocycloalkyl orheteroaryl radical; R′ represents hydrogen and radicals as defined forR³ or R″SO₂— wherein R″ represents radicals as defined for R³; or R andR′ together with the nitrogen to which they are attached representheterocycloalkyl and heteroaryl radical; R¹ represents hydrogen,—CH2SO₂NH₂, —CH₂CO₂Cl₃, —CO₂CH₃, —CONH₂, —CH₂C(O)NHCH₃, —C(CH₃)₂(SH),—C(CH₃)₂(SCH₃), —C(CH₃)₂(S[O]CH₃), —C(CH₃)₂(SiO]2CH₃), alkyl, haloalkyl,alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chainsselected from asparagine, S-methyl cysteine and methionine and thesulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine,allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine,ornithine, histidine, norleucine, glutamine, threonine, glycine,allo-threonine, serine, O-alkyl serine, aspartic acid, beta-cyanoalanine and valine side chains; R¹′ and R¹″ independently representhydrogen and radicals as defined for R¹, or one of R¹′and R¹″, togetherwith R¹ and the carbon atoms to which R¹, R¹′ and R¹″ are attached,represent a cycloalkyl radical; R² represents alkyl, aryl, cycloalkyl,cycloalkylalkyl and aralkyl radicals, which radicals are optionallysubstituted with a group selected from alkyl and halogen radicals, —NO₂,—C_N, CF₃, —OR⁹, —SR⁹, wherein R⁹ represents hydrogen and alkylradicals; R³ represents alkyl, haloalkyl, alkenyl, alkynyl,hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, hererocycloalkylalkyl, aryl, aralkyl,heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkylradicals, wherein said substituents are selected from alkyl, aryl,aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case ofa disubstituted aminoalkyl radical, said substituents along with thenitrogen atom to which they are attached, from a heterocycloalkyl or aheteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkylradicals and the sulfone or sulfoxide derivatives thereof; R⁴ and RSindependently represent hydrogen and radicals as defined by R³ ortogether with a nitrogen atom to which they are bonded form aheterocycloalkyl or a heteroaryl radical; R⁶ represents hydrogen andalkyl radicals; x represents 1 or 2; t represents either 0, 1 or 2; andY represents O, S and NR¹⁵ wherein R¹⁵ represents hydrogen and radicalsas defined for R³.
 2. Compound represented by the formula:

wherein: R represents hydrogen, alkyl, alkenyl, cycloalkyl, aryl,aralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxyalkyl, hydroxyalkyl,alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl,aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyland mono- and disubstituted aminoalkanoyl radicals wherein thesubstituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical isdisubstituted, said substituents along with the nitrogen atom to whichthey are attached form a heterocycloalkyl or heteroaryl radical; R′represents hydrogen and radicals as defined for R³ or R and R′ togetherwith the nitrogen to which they are attached represent heterocycloalkyland heteroaryl radical; R¹ represents hydrogen, —CH2SO₂NH₂, —CH₂CO₂CH3,—CO₂CH₃, —CONH₂, —CH₂C(O)NHCH₃, —C(CH₃)₂(SH), —C(CH3)₂(SCH₃),—C(CH₃)₂(S[O]CH₃), —C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl,alkynyl and cycloalkyl radicals, and amino acid side chains selectedfrom asparagine, S-methyl cysteine and methionine and the sulfoxide (SO)and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine,alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine,norleucine, glutamine, threonine, glycine, allo-threonine, serine,O-methyl serine, aspartic acid, beta-cyanoalanine and valine sidechains; R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl andaralkyl radicals, which radicals are optionally substituted with a groupselected from alkyl and halogen radials, —NO₂, —C≡N, CF₃, —OR⁹, SR⁹,wherein R⁹ represents hydrogen and alkyl radicals; R³ represents alkyl,haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl,aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstitutedaminoalkyl radicals, wherein said substituents are selected from alkyl,aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, beteroaralkyl,heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case ofa disubstituted aminoalkyl radical, said substituents along with thenitrogen atom to which they are attached, form a heterocycloalkyl or aheteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkylradicals and the sulfone or sulfoxide derivatives thereof; R⁴ and R⁵independently represent hydrogen and radicals as defined by R³, ortogether with the nitrogen atom to which they are bonded representheterocycloalkyl and heteroaryl radicals.
 3. Compound of claim 2 whereinR represents aralkoxycarbonyl and heteroaroyl radicals
 4. Compound orclaim 2 wherein R represents carbobenzoxy, 2-benzofurancarbonyl and2-quinolinylcarbonyl radicals.
 5. Compound of claim 2 where R representsacetyl, N,N-dimethylaminoacetyl, N-methylaminoacetyl orN-benzyl-N-methylaminoacetyl.
 6. Compound of claim 2 wherein R¹represents alkyl, alkynyl and alkenyl radicals, and amino acid sidechains selected, from the group consisting of asparagine, valine,threonine, allo-threonine, isoleucine, S-methyl cysteine and the sulfoneand sulfoxide derivatives thereof, alanine, and allo-isoleucine. 7.Compound of claim 2 wherein R¹ represents methyl, propargyl, t-butyl,isopropyl and sec-butyl radicals, and amino acid side chains selectedfrom the group consisting of asparagine, valine, S-methyl cysteine,allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid,beta-cyano alanine, and allo-threonine side chains.
 8. Compound of claim2 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals,which radicals are optionally substituted with halogen radicals andradicals represented by the formula —OR⁹ and —SR⁹ wherein R⁹ representshydrogen and alkyl radicals.
 9. Compound of claim 2 wherein R²represents alkyl, cycloalkylalkyl and aralkyl radicals.
 10. Compound ofclaim 2 wherein R² represents CH₃SCH₂CH₂—, iso-butyl, n-butyl, benzyl,4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals. 11.Compound of claim 2 wherein R³ independently represents alkyl,haloalkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl and heteroaralkylradicals.
 12. Compound of claim 2 wherein R³ represents alkyl,cycloalkyl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocycloalkyl,heterocycloalkylalkyl radicals.
 13. Compound of claim 2 -wherein R³ andR⁴ independently represent alkyl, heterocycloalkyl andheterocycloalkylalkyl radicals.
 14. Compound of claim 2 wherein R³represents isobutyl, n-propyl, isopropyl, n-butyl, isoamyl, cyclohexyl,cyclohexylmethyl, -benzyl and pyridylmethyl radicals.
 15. Compound ofclaim 2 wherein R³ is an isobutyl, n-butyl or isoamyl radical and R⁴ isa tertiary-butyl radical.
 16. Compound of claim 2 wherein R³ is anisobutyl, n-butyl or isoamyl radical and R⁴ is a phenyl radical. 17.Compound of claim 2 wherein R⁴ and R⁵ independently represent hydrogen,alkyl. cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl,heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals. 18.Compound of claim 2 wherein R⁴ and R⁹ independently represent hydrogen,alkyl and aryl radicals.
 19. Compound of claim 2 wherein R⁴ and R⁵independently represent hydrogen, methyl, ethyl, isopropyl, n-butyl,t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenyl radicals. 20.Compound of claim 2 wherein R⁴ and R⁵ together with the nitrogen atom towhich they are bonded form a heterocyloalkyl or heteroaryl radical. 21.Compound of claim 2 wherein R⁴ and R⁵ together with the nitrogen atom towhich they are bonded form a heterocycloalkyl or heteroaryl radicalhaving from 4 to 8 ring members.
 22. Compound of claim 2 wherein R⁴ andR⁵ together with the nitrogen atom to which they are bonded form apyrrolidinyl, piperidinyl, morpholinyl or piperazinyl radical.
 23. Apharmaceutical composition comprising a compound of claim 1 and apharmaceutically acceptable carrier.
 24. A pharmaceutical compositioncomprising a compound of claim 2 and a pharmaceutically acceptablecarrier.
 25. Method of inhibiting a retroviral protease comprisingadministering a protease inhibiting amount of a composition of claim 23.26. Method of claim 25 wherein the recroviral protease is HIV protease.27. Method of treating a retroviral infection comprising administeringan effective amount of a composition of claim
 23. 28. Method of claim 27wherein the retroviral infection is an HIV infection.
 29. Method fortreating AIDS comprising administering an effective amount of acomposition of claim
 23. 30. Method of inhibiting a retroviral proteasecomprising administering a protease inhibiting amount of a compositionof claim
 24. 31. Method of claim 30 wherein the retroviral protease isHIV protease.
 32. Method of treating a retroviral infection comprisingadministering an effective amount of a composition of claim
 24. 33.Method of claim 30 wherein the retroviral infection is an HIV infection.34. Method for treating AIDS comprising administering an effectiveamount of a composition of claim
 24. 35. Compound represented by theformula:

wherein: R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl,cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl,aralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxyalkyl, hydroxyalkyl,aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyland mono- and disubstituted aminoalkanoyl radicals wherein thesubstituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical isdisubstituted, said substituents along with the nitrogen atom to whichthey are attached form a heterocycloalkyl or heteroaryl radical; R¹represents hydrogen and radicals as defined for R³ or R and R′ togetherwith the nitrogen to which they are attached represent heterocycloalkyland heteroaryl radical; R¹ represents hydrogen, —CH₂SO₂NH₂, —CH2CO₂CH3,—CO₂CH₃, —CONH₂, —CH₂C(O)NHCH₃, —C(CH₃)₂(SH), —C(CH₃)₂(SCH₃),—C(CH₃)₂(S[O]CH₃), —C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl,alkynyl and cycloalkyl radicals, and amino acid side chains selectedfrom asparagine, S-methyl cysteine and methionine and the sulfoxide (SO)and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine,alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine,norleucine, glutamine, threonine, glycine, allo-threonine, serine,aspartic acid, beta-cyanoalanine and valine side chains; R² representsalkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, whichradicals are optionally substituted with a group selected from alkyl andhalogen radicals, —NO₂, —C≡N, CF₃, —OR⁹, —SR⁹, wherein R⁹ representshydrogen and alkyl radicals; R³ represents alkyl, haloalkyl, alkenyl,alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl,heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkylradicals, wherein said substituents are selected from alkyl, aryl,aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case ofa disubstituted aminoalkyl radical, said substituents along with thenitrogen atom to which they are attached, form a heterocycloalkyl or aheteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkylradicals and the sulfone or sulfoxide derivatives thereof; R⁴ and R⁵independently represent hydrogen and radicals as defined by R³, ortogether with the nitrogen atom to which they are bonded representheterocycloalkyl and heteroaryl radicals.
 36. Compound of claim 35wherein R¹ represents hydrogen, alkyl, alkenyl and alkynyl radicals. 37.Compound of claim 35 wherein R¹ represents methyl, ethyl, isopropyl,propargyl and t-butyl radicals.
 38. Compound of claim 35 wherein R ishydrogen and R is


39. Compound of claim 35 wherein R, is hydrogen and R represents acetyl,phenoxyacetyl, 2-naphthyloxy-carbonyl, benzyloxycarbonyl,p-methoxybenzyloxycarbonyl.
 40. Compound of claim 35 wherein R and R′are independently selected from methyl and phenethyl radicals. 41.Compound of claim 35 wherein R² represents alkyl, cycloalkylalkyl andaralkyl radicals, which radicals are optionally substituted with halogenradicals and radicals represented by the formula —OR⁹ and —SR⁹ whereinR⁹ represents hydrogen and alkyl radicals.
 42. Compound of claim 35where-n R² represents alkyl, cycloalkylalkyl and aralkyl radicals. 43.Compound of claim 35 wherein R² represents CH₃SCH₂CH₂—, iso-butyl,n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethylradicals.
 44. Compound of claim 35 wherein R² represents benzyl,4-fluorobenzyl, and 2-naphthylmethyl radicals.
 45. Compound of claim 35wherein R³ independently represents alkyl, haloalkyl, alkenyl,alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,heterocycloalkylalkyl, aryl, aralkyl and heteroaralkyl radicals. 46.Compound of claim 35 wherein R) represents alkyl, cycloalkyl,cycloalkylalkyl, aralkyl, heteroaralkyl, heterocycloalkyl,heterocycloalkylalkyl radicals.
 47. Compound of claim 35 wherein R³ andR⁴ independently represent alkyl, heterocycloalkyl andheterocycloalkylalkyl radicals.
 48. Compound of claim 35 wherein R′represents isobutyl, n-propyl, isopropyl, n-butyl, isoamyl, cyclohexyl,cyclohexylmethyl, benzyl and pyridylmethyl radicals.
 49. Compound ofclaim 35 wherein R³ is an isobutyl, n-butyl or t-butyl radical and R⁴ isa t-butyl radical.
 50. Compound of claim 35 wherein R³ is an isobutyl,n-butyl or isoamyl radical and R⁴ is a phenyl radical.
 51. Compound ofclaim 35 wherein R⁴ and R⁵ independently represent hydrogen, alkyl,cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl,heterocycloalkyl and heterocycloalkylalkyl radicals.
 52. Compound ofclaim 35 wherein R⁴ and R⁵ independently represent hydrogen, alkyl andaryl radicals.
 53. Compound of claim 35 wherein R⁴ and R⁵ independentlyrepresent hydrogen, methyl, ethyl, isopropyl, n-butyl, cyclohexyl,t-butyl, 1,1-dimethylpropyl and phenyl radicals.
 54. Compound of claim35 wherein R⁴ and R⁵ together with the nitrogen atom to which they arebonded form a heterocyloalkyl or heteroaryl radical.
 55. Compound ofclaim 35 wherein R⁴ and R⁵ together with the nitrogen atom to which theyare bonded form a heterocycloalkyl or heteroaryl radical having from 4to 8 ring members.
 56. Compound of claim 35 wherein R⁴ and R⁵ togetherwith the nitrogen atom to which they are bonded form a pyrrolidinyl,piperidinyl, morpholinyl or piperazinyl radical.
 57. A pharmaceuticalcomposition comprising a compound of claim 35 and a pharmaceuticallyacceptable carrier.
 58. Method of inhibiting a retroviral proteasecomprising administering a protease inhibiting amount of a compositionof claim
 57. 59. Method of claim 58 wherein the retroviral protease isHIV protease.
 60. Method of treating a retroviral infection comprisingadministering an effective amount of a composition of claim
 57. 61.Method of claim 60 wherein the retroviral infection is an HIV infection.62. Method for treating AIDS comprising administering an effectiveamount of a composition of claim
 57. 63. Compound represented by theformula:

wherein: R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl,cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl,aralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxyalkyl, hydroxyalkyl,aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyland mono- and disubstituted aminoalkanoyl radicals wherein thesubstituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical isdisubstituted, said substituents along with the nitrogen atom to whichthey are attached form a heterocycloalkyl or heteroaryl radical; R′represents hydrogen and radicals as defined for R³ or R and R′ togetherwith the nitrogen co which they are attached represent heterocycloalkyland heteroaryl radical; R¹ represents hydrogen, —CH₂SO₂NH₂, —CH₂CO₂CH₃,—CO₂CH₃, —CONH₂, —CH₂C(O)NHCH₃, —C(CH₃)₂(SH), —C(CH₃)₂(SCH₃),—(CH₃)₂(S[O]CH₃), —C(CH₃)₂(S[O]₂CH₃—, alkyl, haloalkyl, alkenyl, alkynyland cycloalkyl radicals, and amino acid side chains selected fromasparagine, S-methyl cysteine and methionine and the sulfoxide (SO) andsulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine,leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine,glutamine, threonine, glycine, allo-threonine, serine, aspartic acid,beta-cyano alanine and valine side chains; R¹′ and R¹″ independentlyrepresent hydrogen and radicals as defined for R¹, or one of R¹′ andR¹″, together with R¹ and the carbon atoms to which R¹, R¹′ and R¹″ areattached, represent a cycloalkyl radical; R² represents alkyl, aryl,cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals areoptionally substituted with a group selected from alkyl and halogenradials, —NO₂, —C≡N, CF₃, —OR⁹, —SR⁹, wherein R⁹ represents hydrogen andalkyl radicals; R³ represents alkyl, haloalkyl, alkenyl, alkynyl,hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl,heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkylradicals, wherein said substituents are selected from alkyl, aryl,aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case ofa disubstituted aminoalkyl radical, said substituents along with thenitrogen atom to which they are attached, form a heterocycloalkyl or aheteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkylradicals and the sulfone or sulfoxide derivatives thereof; R⁴ and R⁵independently represent hydrogen and radicals as defined by R³, ortogether with the nitrogen atom to which they are bonded representheterocycloalkyl and heteroaryl radicals.
 64. Compound of claim 63wherein R′ represents hydrogen and R represents aralkoxycarbonyl andheteroaroyl radicals.
 65. Compound of claim 63 wherein R′ is hydrogenand R represents carbobenzoxy, -benzofurancarbonyl, and2-quinolinylcarbonyl radicals.
 66. Compound of claim 63 wherein R′ ishydrogen and R is 2-quinolinylcarbonyl.
 67. Compound of claim 63 whereinR¹, R¹′ and R¹″ independently represent hydrogen and alkyl radicalshaving from 1 to about 4 carbon atoms, alkenyl, alkynyl, aralkylradicals and radicals selected from —CH₂SO₂NH₂, —CO₂CH₃, —CONHCH₃,—CON(CH₃)₂₁—CH₂C(O)NHCH₃, —CH₂C(O)N(CH₃)₂₁—CONH₂, —C(CH₃)₂(SCH₃),—C(CH₃)₂(S[O]CH₃, and —C(CH₃)₂(S[O]CH₃).
 68. Compound of claim 63wherein R¹, R¹′ and R¹″ independently represent hydrogen, methyl, ethyl,benzyl, phenylpropyl, propargyl, hydroxyl and radicals selected from—C(O)OCH₃, —C(O)NH₂, —C(O)OH.
 69. Compound of claim 63 wherein R¹ andR¹′ are both hydrogen and R¹″ is C(O)NH_(2.)
 70. Compound of claim 63wherein R represents aralkoxycarbonyl and heteroaroyl radicals. 71.Compound of claim 63 wherein R¹ and R¹′ are both hydrogen and R¹″ ismethyl.
 72. Compound of claim 63 wherein R¹′ is hydrogen and R¹ and R¹″together with the carbon atoms to which they are attached form a threeto six-membered cycloalkyl radical.
 73. Compound of claim 63 wherein Ris carbobenzoxy, 2-quinolinylcarbonyl and 2-benzofuran carbonylradicals.
 74. Compound of claim 63 wherein R¹ and R¹′ are both hydrogenand R¹″ is propargyl.
 75. Compound of Claim 63 wherein R² representsalkyl, cycloalkylalkyl and aralkyl radicals, which radicals areoptionally substituted with halogen radicals and radicals represented bythe formula —CR⁹ and —SR¹ wherein R⁹ represents hydrogen and alkylradicals.
 76. Compound of claim 63 wherein R² represents alkyl,cycloalkylalkyl and aralkyl radicals.
 77. Compound of claim 63 whereinR² represents aralkyl radicals.
 78. Compound of claim 63 wherein R³independently represents alkyl, haloalkyl, alkenyl, alkoxyalkyl,cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl,aryl, aralkyl and heteroaralkyl radicals.
 79. Compound of claim 63wherein R³ represents alkyl, cycloalkyl, cycloalkylalkyl, aralkyl,heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals. 80.Compound of claim 63 wherein R³ and R⁴ independently represent alkyl,heterocycloalkyl and heterocycloalkylalkyl radicals.
 81. Compound ofclaim 63 wherein R³ represents isobutyl, n-propyl, isopropyl, n-butyl,isoamyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethylradicals.
 82. Compound of claim 63 wherein R³ is an isobutyl, n-butyl orisoamyl radical and R⁴ is a tert-butyl radical.
 83. Compound of claim 63wherein R³ is an isobutyl, n-butyl or isoamyl radical and R⁴ is a phenylradical.
 84. Compound of claim 63 wherein R⁴ and R⁵ independentlyrepresent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl,heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl andheterocycloalkylalkyl radicals.
 85. Compound of claim 63 wherein R⁴ andR⁵ independently represent hydrogen, alkyl and aryl radicals. 86.Compound of claim 63 wherein R⁴ and R⁵ independently represent hydrogen,methyl, ethyl, isopropyl, n-butyl-, t-butyl, cyclohexyl,1,1-dimethylpropyl and phenyl radicals.
 87. Compound of claim 63 whereinR⁴ and R⁵ together with the nitrogen atom to which they are bonded forma heterocyloalkyl or heteroaryl radical-.
 88. Compound of claim 63wherein R⁴ and R⁵ together with the nitrogen atom to which they arebonded form a heterocycloalkyl or heteroaryl radical having from 4 to 8ring members.
 89. Compound of claim 63 wherein R⁴ and R⁵ together withthe nitrogen atom to which they are bonded form a pyrrolidinyl,piperidinyl, morpholinyl or piperazinyl radical.
 90. A pharmaceuticalcomposition comprising a compound of claim 63 and a pharmaceuticallyacceptable carrier.
 91. Method of inhibiting a retroviral proteasecomprising administering a protease inhibiting amount of a compositionof claim
 89. 92. Method of claim 90 wherein the retroviral protease isHIV protease.
 93. Method of treating a retroviral infection comprisingadministering an effective amount of a composition of claim
 89. 94.Method of claim 92 wherein the retroviral infection is an HIV infection.95. Method for treating AIDE comprising administering an effectiveamount of a composition of claim
 89. 96. A compound of claim 1 which is:N-[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[[(dimethylamino)-1-oxoethyl]amino]dimethylbutanamide;N-[3-[[(methylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[[2-(dimethylamino)-1-oxoethyl]amino]dimethylbutaneamide;N1-[2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide;N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide; N1-[3-[[(1,1-dimethylentyll)amino]sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-[phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino)butanediamide;N′-[3-[[phenylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide;or N′-[3-[[cyclohexylaminolsulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)zropyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide.97. A compound represented by the formula:

wherein: P¹ and P² independently represent hydrogen, alkoxycarbonyl,aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl,heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl,aralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxyalkyl, hydroxyalkyl,aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyland mono- and disubstituted aminoalkanoyl radicals wherein thesubstituents are selected from alkyl, aryl, aralkyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical isdisubstituted said substituents along with the nitrogen atom to whichthey are attached form a heterocycloalkyl or heteroaryl radical; R²represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkylradicals, which radicals are optionally substituted with a groupselected from alkyl and halogen radicals, —NO₂, —C_N, CF₃, —OR⁹, —SR⁹,wherein R⁹ represents hydrogen and alkyl radicals; R³ representshydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl,cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl andmono- and disubstituted aminoalkyl radicals, wherein said substituentsare selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkylradicals, or in the case of a disubstituted aminoalkyl radical, saidsubstituents along with the nitrogen atom to which they are attached,form a heterocycloalkyl or a heteroaryl radical, and thioalkyl,alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxidederivatives thereof; R⁴ and R⁵ independently represent hydrogen andradicals as defined by R³ or together with a nitrogen atom to which theyare bonded form a heterocycloalkyl or a heteroaryl radical.
 98. Compoundof claim 97 wherein R³ represents alkyl, haloalkyl, alkenyl, alkynyl,hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl,heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkylradicals, wherein said substituents are selected from alkyl, aryl,aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case ofa disubstituted aminoalkyl radical, said substituents along with thenitrogen atom to which they are attached, form a heterocycloalkyl or aheteroaryl radical; and R⁴ and R⁵ independently represent hydrogen andradicals as defined by R³, or together with the nitrogen atom to whichthey are bonded represent heterocycloalkyl and heteroaryl radicals. 99.A pharmaceutical composition comprising a compound of claim 97 and apharmaceutically acceptable carrier.
 100. Method of inhibiting aretroviral protease comprising administering a protease inhibitingamount of a composition of claim
 99. 101. Method of claim 100 whereinthe retroviral protease is HIV protease.
 102. Method of treating aretroviral infection comprising administering an effective amount of acomposition of claim
 99. 103. Method of claim 101 wherein the retroviralinfection is an HIV infection.
 104. Method for treating AIDS comprisingadministering an effective amount of a composition of claim
 99. 105.Compound of claim 97 which is:phenylmethyl[2R-hydroxy-3-[[(dimethylamino)sulfonyl](2-methylpropyl)amino]-1S— (phenylmethyl)propyl] carbamate;phenylmethyl[2R-hydroxy-3-[[(dimethylamino)sulfonyl](3-methylbutyl)amino]-1s-(phenylmethyl)propy]carbamate; phenylmethyl[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl] carbamate;phenylmethyl [2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate; phenylmethyl[2R-hydroxy-3-[[(1,1-dimethyl)amino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate; phenylmethyl[2R-hydroxy-3-[[methylamino)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate; phenylmethyl[2R-hydroxy-3-[[(methylethyl)amino]-sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate; phenylmethyl[2R-hydroxy-3-[[phenylamino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate; phenylmethyl[2R-hydroxy-3-[[cyclohexylaminol]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate; orphenylmethyl [2R-hydroxy-3-[[(1pyrrolidinyl)amino]-sulfonyl](2-methylproptyl)amino]-1s-(phenylmethyl propyl] carbamate.